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Abstract: 
 
POSITRON EMISSION TOMOGRAPHY FOR PRE-CLINICAL SUB-VOLUME DOSE 
ESCALATION 
 
By Christopher Paul Bass 
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy in Medical Physics at Virginia Commonwealth University. 
Virginia Commonwealth University, 2013 
Major Director: Andrei Pugachev, Staff medical physicist, Radiation Oncology 
Purpose: 
This dissertation focuses on establishment of pre-clinical methods facilitating the use of 
PET imaging for selective sub-volume dose escalation. Specifically the problems addressed are 
1.) The difficulties associated with comparing multiple PET images, 2.) The need for further 
validation of novel PET tracers before their implementation in dose escalation schema and 3.) 
The lack of concrete pre-clinical data supporting the use of PET images for guidance of selective 
sub-volume dose escalations.   
Methods and materials: 
In order to compare multiple PET images the confounding effects of mispositioning and 
anatomical change between imaging sessions needed to be alleviated. To mitigate the effects of 
these sources of error, deformable image registration was employed.  A deformable registration 
algorithm was selected and the registration error was evaluated via the introduction of external 
fiducials to the tumor. Once a method for image registration was established, a procedure for 
validating the use of novel PET tracers with FDG was developed. Nude mice were used to 
xii 
 
perform in-vivo comparisons of the spatial distributions of two PET tracers, FDG and FLT. The 
spatial distributions were also compared across two separate tumor lines to determine the effects 
of tumor morphology on spatial distribution. Finally, the research establishes a method for 
acquiring pre-clinical data supporting the use of PET for image-guidance in selective dose 
escalation. Nude mice were imaged using only FDG PET/CT and the resulting images were used 
to plan PET-guided dose escalations to a 5 mm sub-volume within the tumor that contained the 
highest PET tracer uptake. These plans were then delivered using the Small Animal Radiation 
Research Platform (SARRP) and the efficacy of the PET-guided plans was observed.   
Results and Conclusions: 
The analysis of deformable registration algorithms revealed that the BRAINSFit B-spline 
deformable registration algorithm available in SLICER3D was capable of registering small 
animal PET/CT data sets in less than 5 minutes with an average registration error of .3 mm. The 
methods used in chapter 3 allowed for the comparison of the spatial distributions of multiple 
PET tracers imaged at different times. A comparison of FDG and FLT showed that both are 
positively correlated but that tumor morphology does significantly affect the correlation between 
the two tracers. An overlap analysis of the high intensity PET regions of FDG and FLT showed 
that FLT offers additional spatial information to that seen with FDG. In chapter 4 the SARRP 
allowed for the delivery of planned PET-guided selective dose escalations to a pre-clinical tumor 
model. This will facilitate future research validating the use of PET for clinical selective dose 
escalation.   
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Chapter 1: Introduction  
 
This dissertation focuses on establishing pre-clinical methodologies for in-vivo validation of 
the use of PET in treatment planning; specifically, the utility of Fluorodeoxyglucose (FDG) PET 
imaging in guiding dose escalation to a tumor sub-volume. Additionally pre-clinical methods for 
examining the potential of novel PET tracers to provide additional information to FDG are 
established. This introduction provides background physics and summary of how PET imaging 
could be used to increase tumor control in radiation oncology.  
1.1. Lack of Improvements in Cancer Survival Rate 
Since the 1970s there have been many advances in the field of radiation therapy. Primary 
imaging modalities have changed from 2D radiographic x-rays to combined modality PET/CT 
tomographic images. Planning methodologies have improved from manually-placed forward 
calculated plans to inverse plans in which the desired dose can be specified by the dosimetrist 
and the plan is created and optimized by a computer. Beam collimation has shifted from the 
primary jaw collimation to multi-leaf collimators allowing for intensity modulation and more 
conformal beam shaping [1]. Despite all of the advances in the fields of radiation therapy and 
medical imaging since the 1970s, overall patient survival rates show only a small improvement  
[2], [3]. In head and neck cancer specifically, Pulte et al. showed that from 1982 to 2006 survival 
rates for head and neck cancer have gone from 52.7 % to 65.9% [4].  
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Reexamining the historical development of radiation therapy it becomes obvious that the one 
aspect that has never changed is the goal of treatment planning; to deliver a homogeneous 
radiation dose to a gross tumor volume (GTV) defined on anatomical imaging. This approach 
accounts only for the spatial extent of the GTV while neglecting the underlying tumor biology 
[5], [6], [7]. Histopathological studies of both patient tumor specimens [5], [8] and small animal 
tumor xenograft models have shown that tumors exhibit highly heterogeneous microscopic 
biological features (figure 1). 
Unfortunately, while histological analyses can yield information regarding tumor biology, it 
is an invasive procedure and cannot be carried out prior to radiation therapy. In 2000, Ling et al. 
proposed to use PET imaging of multiple different novel PET tracers to gain insight into 
underlying tumor biology non-invasively.  Ling proposed that cancer survival rates could be 
improved by treating each tumor with a heterogeneous dose distribution sculpted to the specific 
radio-resistances of tumor cells as derived from PET images [9]. 
 
Figure 1 :A.) A CT image of a FaDu head and neck depicting a mass of homogeneous density. B.) An 
immunofluorescence image of a FaDu tumor which shows the heterogeneity of the underlying tumor biology.  Both images are 
from a mouse xenografts model. 
 
Figure 1.) 
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1.2. Introduction to PET physics 
Unlike computed tomography (CT) and magnetic resonance imaging (MRI), which are 
principally utilized for anatomical imaging, positron emission tomography (PET) is a functional 
imaging modality which provides visualization of underlying molecular processes within the 
biological tissues. For PET imaging, a positron-emitting imaging probe, a chemical compound 
labeled with a positron emitter, is injected into the subject and is taken up more avidly by tissues 
expressing specific biological properties. Following the uptake period, the patient is scanned 
using a dedicated scanner which uses scintillation crystals aligned in a ring around the patient. 
When the radio-nuclide decays, a positron is emitted. The positron travels through the tissue for 
some distance within tissue, eventually coming to rest and annihilating with an electron (figure 
2).  
 
Figure 2: Depiction of a positron emitter (red) emitting a positron (< - - -) which annihilates with an electron (           ) 
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The positron-electron system produces two nearly parallel-opposed 511 KeV gamma rays. 
When the scintillation crystals detect two coincident 511 KeV gamma rays, a single positron 
annihilation event is registered between the two detector crystals. After detection of the two 
gamma rays, a line between the detectors along which the annihilation event occurred, known as 
the line of response, is identified (Figure 3). 
After the detection of many annihilation events, the various lines of response are used to 
estimate the distribution of PET tracer within the image space. 
  While PET imaging does provide insight into the underlying biological properties of 
tissues it suffers from a lower resolution when compared with anatomical imaging modalities 
such as CT or MRI. Resolution-limiting factors can be broken into two categories, intrinsic 
 
Figure 3: Depiction of a hypothetical line of response (red line) resulting from the detection of 
two co-incident 511 KeV photons (             ) 
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factors, factors that are inherent to PET imaging, and extrinsic factors, factors that are specific to 
scanner design. The three for the most dominant resolution limiting factors for PET imaging are 
positron range in tissue,   the emission of non-parallel opposed gamma rays and scintillation 
detector related factors [10], [11].  
Positron range in tissue is an intrinsic limitation of PET resolution. Due to the fact that 
positrons emitted from 18F travel some distance in tissue before annihilating, the system is 
detecting the position of the positron annihilation event, which is at best an approximation to the 
location of the positron-emitting probe. This phenomenon introduces a resolution-limiting 
uncertainty into the location of the tracer.  Another intrinsic resolution-limiting factor is the non-
parallel opposed emission of gamma rays. In creating a line of response it is assumed that the 
positron and electron pair were at rest when annihilation occurred, resulting in two gamma rays 
emitted parallel opposed to one another because of conservation of momentum. It is possible, 
however, for the positron to annihilate with an electron without coming to complete rest. In this 
case the two gamma rays emitted from the annihilation event will not be parallel opposed; 
resulting in a line of response that is not representative of the location the annihilation occurred 
(Figure 4). 
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Resolution is also limited by extrinsic, machine specific factors, such as the choice of 
detectors of the PET system. Due to the fact that scintillation detectors cannot be infinitely small, 
there is a resolution limitation introduced by the finite size of the detector crystal. Due to the 
design of most commercial PET systems, the gamma rays incident upon a detector are 
localizable only within the size of the detector. In other words, if two gamma rays were incident 
upon the same detector but 1 cm apart from one another, both incidents would be spatially 
indistinguishable. As a result the line of response drawn from two detectors is limited in width 
by the size of the detector (Figure 5). 
 
 
Figure 4: Figure depicting the emission of non-parallel opposed photons and resulting skewed line 
of response which is not representative of the position of the annihilation event. 
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In addition to these resolution-limiting factors, random coincidences and scatter within tissue 
can also introduce uncertainties into PET images. Random coincidences occur when two 
separate annihilation events produce gamma rays and the system misregisters the arrival of two 
gamma rays originating from two different annihilation events as coincident gamma rays from a 
single event (Figure 6). 
 
Figure 6: Figure depicting the occurrence of a random coincidence (photons from two 
separate annihilations registering as the same event) and the resulting line of response which is 
not representative of the position of either annihilation 
 
 
Figure 5: The effect of detector size on the intrinsic line of response modeled with a large detector (Left) and a 
small detector (Right) 
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 This misregistration results in a line of response that does not correspond to either of the 
annihilation events, introducing uncertainty into the results of imaging.  
Gamma rays from a single annihilation event can also be scattered either in tissue or in the 
detectors themselves. In tissue, gamma rays in the 511 KeV energy range can collide with 
electrons in the tissue. After collision, the incident gamma ray transfers some fraction of its 
energy to the electron and the gamma ray is deflected by an angle theta given by the equation for 
Compton interaction:  
' (1 cos )
e
h
m c
      
Where h is Planck’s constant, me is the mass of an electron, c is the speed of light, theta is the 
angle the gamma ray scatters, lambda is the original gamma ray energy and lambda prime is the 
new energy of the gamma ray after collision. In order to limit the effects of noise and scattering 
events, PET systems have a specific energy window for coincidence detection. An energy 
window is a specific range of energies that are accepted as products of annihilation events. Only 
accepting incident gamma rays with energy of exactly 511 KeV can minimize the effect of these 
scattering events but could also potentially increase the time needed to complete a scan (Figure 
7). 
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Overall, these effects result in a resolution of approximately 5 mm for clinical whole body 
patient scanners and approximately 1.5 mm for dedicated small animal scanners [10]. Despite the 
limited resolution compared to anatomical imaging modalities like CT, PET provides a non-
invasive method for gaining insight into the underlying biological processes in tumors prior to 
treatment. Pairing PET with CT anatomical imaging allows for these biological processes to be 
localized within the resolution of the PET scan.  
1.3. Current uses and limitations of PET and Molecular Imaging in the clinic 
 
Outside of clinical trials, most clinics exclusively use 
18
Fluorine-Fluorodeoxyglucoe or FDG, 
which is a glucose analogue. Tissues exhibiting high glucose metabolism do not differentiate 
between glucose and FDG and subsequently uptake more FDG than normal tissues. Once in a 
cell, however, FDG is phosphorylated and becomes trapped due to a missing hydroxyl group 
needed for glycolysis. In this way FDG can be accumulated over time. The differences in amount 
of FDG retention in cells produces the image contrast seen in PET images.  
 
Figure 7: Figure depicting a scattering event of a single photon (           ) and the 
resulting line of response which is not representative of the position of annihilation event 
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 Differences in glucose metabolism from cell to cell in tumors have been shown to have a 
variety of causes including: the presence of hypoxia, cells with high proliferation rates, and local 
differences in tumor cell density [7]. Consequently, FDG is not a specific tracer of any one 
biological phenomenon. Rather, it represents a complicated interplay of multiple biological 
phenomena within the tumor. This increase in glucose metabolism and consumption does not 
necessarily more aggressive disease or higher risk of recurrence. Due to its non-specificity to any 
one underlying biological property, PET images are typically used in the clinic as binary 
indicators of lymph node involvement as sub-clinical and metastatic disease.  
Despite its limitations, multiple studies suggest that FDG has potential for other clinical uses 
such as therapy response monitoring, primary tumor delineation, a basis for treatment planning, 
and making clinical decisions on treatment modality using tracer uptake [12], [13], [14]. 
However, it has also been suggested that FDG be combined with tracers of other biological 
phenomena by labeling substances other than Fluorodeoxyglucose with 
18
F. It has been 
suggested that performing multiple PET studies using different novel PET tracers would 
overcome the limitations of FDG alone and provide additional information useful for clinical 
decision making [9].  
   
1.4. Potential for using multiple PET tracers for radiotherapy guidance 
 
1.4.1. The rationale for multiple-tracer PET imaging 
 
In order to achieve an improvement in tumor control it has been suggested that PET imaging 
be used to escalate doses to CT defined GTVs [9], [15]. The current strategy for dose escalation 
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using PET imaging is to escalate dose to the entire tumor as it is defined on FDG PET imaging 
[16], [17], [18], [19]. The rationale behind the escalation of the entire tumor is that on PET-
positive volumes are significantly smaller than CT defined GTVs. This smaller target volume has 
been shown to allow for the delivery of a slightly escalated dose to the tumor before organs at 
risk reach their dose-limiting constraints [16], [17], [18], [19]. As previously stated, however, 
FDG is not indicative of increased radioresistance within a tumor. Increasing the dose to the 
entire FDG-avid tumor is likely to be excessive and normal tissue structures will reach toxicity 
sooner than with smaller escalation sub-volumes.  
Ling et al. suggested the implementation of a multiple-tracer PET imaging protocol that 
would allow for the identification of the specific biological heterogeneities within a tumor, for 
example areas of hypoxia or proliferating cells [9], [15]. Hypoxic cells and proliferating cells 
both exhibit distinctly different radiosensitivities. During radiotherapy well oxygenated cells 
experience increased damage due to the production of free radicals. Hypoxic cells, however, do 
not experience any of this increased cellular damage when irradiated and as a result are more 
radioresistant.  Rapidly proliferating cells also exhibit different radiosensitivity than normal 
cells. Cells undergoing rapid proliferation are more likely irradiated in M and G2 phases of the 
cell cycle. In these phases it is much easier to achieve double strand DNA breaks and as such 
these cells are typically more sensitive to irradiation.  Chemical compounds such as 
fluorothymidine and fluoromisonidazole can be labeled with radioactive fluorine and used to 
visualize areas of increased cellular proliferation and hypoxia respectively. By identifying these 
sub-populations of tumors cells, Ling proposed to create a map of the underlying tumor biology 
prior to treatment. This map of biological features could then be used to modify the dose 
prescription in such a way as to treat the underlying biological and radiological properties of 
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each individual tumor [9]. Identifying these specific sub-populations of cells prior to radiation 
therapy would allow physicians to escalate doses to areas of increased risk of recurrence rather 
than to the entire tumor unilaterally and could decrease toxicity associated with escalated doses. 
 
1.4.2. The need for validation of novel PET tracers 
 
The use of non-FDG PET tracers to obtain multiple PET images representative of different 
biological features of interest, is still an area of continuing research. The benefits of using 
multiple PET tracers to acquire information that would benefit clinical practice have yet to be 
evaluated in detail [15], [20].  While the biological mechanisms of uptake are different between 
FDG, FLT and F-Miso, for example, biological factors such as vascularization of the tumor and 
necrosis can potentially limit the benefit of using multiple tracers. Large areas of necrosis and 
poorly vascularized tumors can cause the distribution of tracers to be limited within the tumor. 
When these tracers are then imaged, the limited resolution of PET combined with the limited 
tracer distribution within the tumor could result in very similar tracer distributions. To this end, it 
is important to ensure that the effects of tumor morphology do not force tracers of different 
biological properties to exhibit the same spatial distributions. This is not an easy phenomenon to 
examine, however, because changes such as physical mispositioning of the subject and 
anatomical changes confound the ability to compare the true spatial distributions of PET tracers 
within tumors. Prior to attempting further validating of novel PET tracers, a methodology must 
be set to remove the effects of these confounding factors. 
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1.5. Specific Aims of the research 
 
In order to achieve better tumor control and patient survival rates Ling et al. suggest that the 
underlying biological features of a tumor need to be taken into consideration when creating a 
treatment plan. Specifically, the radioresistances of cells within the tumor should be determined 
and dose should be assigned accordingly. The specific aims of this dissertation discuss the tools 
and methodologies needed to perform biologically-guided dose escalations using a pre-clinical 
model. Chapter 2 discusses the difficulties associated with comparing images acquired at 
different points in time for use in treatment planning, and the role deformable image registration 
can play in alleviating mispositioning errors and changes in anatomy between imaging sessions. 
Specifically, deformable registration algorithms are validated for the accuracy needed to deform 
small animal pre-clinical PET images. Chapter 3 uses the deformable registration protocol 
explored in the previous chapter to compare the spatial distribution of FDG to the distribution of 
other novel tracers. For the purposes of establishing the methodology 
18
F-Fluorothymidine 
(FLT), a novel PET tracer of proliferation, is compared with FDG. The co-localization of the two 
tracers is analyzed to determine the utility of FLT in conjunction with FDG. Chapter 4 outlines a 
protocol for planning and delivering PET-guided dose escalations on a small animal model using 
the Small Animal Radiation Research Platform (SARRP), image-guided small animal irradiator. 
As an illustration, a pilot study comparing FDG-guided dose escalation and an arbitrarily placed 
dose escalation was also carried out to test the efficacy of this protocol.  
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Figure 8: A comparison of Two CT images of the same animal on consecutive days depicting the changes in anatomy 
and positioning from day to day. The green contour signifies the first day’s body contour, purple the body contour on the 
second day. The yellow and blue contours represent the first day tumor positions. 
 
Chapter 2: Validation of deformable registration algorithms for PET 
images  
2.1. Background and Rationale 
Differences in the spatial distributions of PET tracers can be attributed to three main causes: 
Changes caused by deforming internal anatomy, changes caused by physical mispositioning and 
changes in the underlying biological processes governing tracer uptake. The goal of most 
imaging used in radiation oncology is to observe differences in anatomy caused by positioning or 
anatomical changes. The comparison of functional images, however, is confounded by these 
sources of change. In order to properly compare functional medical images acquired at two 
different times it is important to have an objective methodology for removing effects of changes 
induced by anatomical and positioning differences (Figure 8). 
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2.2. Deformable Image Registration 
 
Deformable image registration can serve as a method for alleviating the effects of errors in 
positioning and anatomical changes. Image registration is an iterative process in which an 
estimated transformation is determined by the results of the optimizer and the transformed image 
is compared to the fixed image. If the fixed and transformed images meet a defined similarity 
criteria and the optimizer can find no better result, then the image is considered registered from 
the program’s point of view.  
There are three main components of any deformable registration algorithm [23], [24], 
[25]: 
1. The deformation model, which determines how the moving image can be changed 
2. The cost function, which is a measure of  agreement of the transformed image 
registration and the fixed image set 
3. The optimizer, which is the methodology used to iteratively minimize or maximize 
the cost function until an acceptable value is reached 
These components are further described in the following sections. 
 
2.2.1. The Deformable Model  
The registration model determines the physical properties and constraints on the 
registration. A registration model must be selected for the appropriate application for the 
scale of the changes needed: large global changes or small local changes. Some of the most 
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commonly discussed models include Basis-spline (B-spline) and the diffusion-based 
Demons’ [23], [24], [25], [26] 
2.2.1.1. Basis spline models 
The two major spline-based models are the thin-plate spline model and the B-spline model. 
The B-spline model defines a grid of control points on both images. The resolution of this 
control point grid is defined by the user, with sparse grids resulting in large-scale deformations 
and finer grids contributing to small local changes. The deformable transform in three 
dimensions is represented as a series of cubic piecewise polynomials which are centered on the 
control points [24], [25]. The deformation is determined by summing the polynomials across 
small local regions of the image. The weighting at each of these control points controls the 
magnitude of deformation in the image. It is important to note, however, that with a large 
number of control points, changing the coefficient of a single control point will have a limited 
range of influence and will not affect the global image [23], [24], [25].  
2.2.1.2. Demons’ deformation models 
Thirion et al. proposed to approach the problem of image registration as a diffusion problem 
in their 1998 paper [27]. In the paper, Thirion describes the fixed image as being a semi-
permeable membrane. The moving image is considered a deforming grid and is pulled into the 
semi-permeable fixed image by hypothetical forces at each of the grid control points. Thirion 
defines the process of deforming medical images in four steps. 
1. A control point called a demon is placed at the center of each voxel in the moving 
image  
2. The “Demon’s force”,   ,responsible for the displacement for each point in the 
moving image is calculated using the optical flow equation for instantaneous velocity: 
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Where m is the intensity of the point in the moving image and s is the intensity of the 
point in the fixed image 
3. A free form deformation is then established by repeating the calculation of the 
Demon’s force for each voxel in the moving image 
4. A Gaussian smoothing function is used to smooth the free form deformation over the 
entire image to regularize the transformation 
This general algorithm formulation is known as the Demons’ deformation algorithm [27].  
2.2.2. Cost Functions 
The cost function of the algorithm is a mathematical expression which is designed to 
maximize the similarity between the fixed and transforming images.  The optimizer of the 
algorithm iteratively attempts to minimize the value of the cost function to achieve the best 
registration.  In general the cost functions compare either pre-defined physical landmarks in the 
images or the gray scale image intensities. Landmark-based algorithms use manual or 
automatically selected features that are present in both images to drive the registration. This is 
beneficial because anatomical landmarks ensure that the image registration remains anatomically 
correct. In contrast, image registration algorithms using intensity-based cost functions only take 
into account the grayscale intensities of the pixels of the image without knowledge of anatomical 
structures. Without any sort of constraints on the transformation, it would be possible for an 
intensity-based algorithm to exacerbate the misalignments of structures.  
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Common cost functions include sum of squared distances, correlation coefficient methods 
and mutual information. Mutual information, the cost function implemented in this dissertation, 
involves maximizing the concordance of areas with similar gray scale intensities. Klein et al. 
describe the mutual information cost function as: 
       ∑ ∑             (
      
          
)
        
   
Where µ is defined as a vector containing the b-spline coefficients and is a function of the 
intensity of the moving image, Im, and the intensity of the fixed image, If. Lm and Lf are intensity 
bins of the moving and fixed images, p is defined as the joint probability function of the fixed 
and moving images and PF and PM are the probability of the fixed and moving images. 
Additional details about the Thevenaz method are described in Klein’s paper [29]. Another 
method of computing the mutual information metric seen in the review paper by zitova et al. 
defines MI as: 
                    
Where H(M) is the entropy function of the moving image, H(F) is the entropy function of the 
fixed image set and H (M,F) is the joint entropy function of both image sets [22]. Both of these 
methodologies have been tested and are commonly used for multimodal image registration. In a 
study of similarity measure efficiency Boyd et al. determined that mutual information was ideal 
due to its ability to register images of different anatomical modalities and was efficient enough 
for quick image registrations.  
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2.2.3. Optimizers 
There are a great number of optimization methods available for implementation in 
deformable image registration. The optimizer used throughout the most of this dissertation is a 
steepest gradient descent approach.  The steepest gradient descent algorithm attempts to 
minimize the cost function by finding the greatest rate of change in the B-spline coefficients to 
drive the cost function iteratively towards a minimum value quickly. Klein et al. describes the 
process mathematically as: 
                 
Where    is the previous set of B-spline coefficient parameters selected by the optimizer, 
   is a factor limiting the step size that the algorithm may take and        is the derivative of the 
cost function with respect to the current set of B-spline parameters [29]. This process is 
performed until the cost function reaches a local minimum. In a review of optimizers by Maes et 
al., the steepest gradient descent optimizer was suggested to be the easiest to implement 
optimizers [30]. This optimizer doses, however, suffer from the fact that the local minimum of 
the cost function is not always going to be the global minimum. This implies that is could be 
possible for better solutions for the registration than what algorithm is returning at any given 
time.  In addition, Klein et al. found the steepest gradient descent method to function more 
slowly than other methods [29]. Despite this the gradient descent method used in this research 
performed registrations in less than 3 minutes on average depending on parameters selected. It 
may be possible to improve this time by implementing other optimization schemes. 
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2.3. Algorithm selection 
 
The application of deformable image registration to pre-clinical biological images requires an 
algorithm which can handle primarily large shifts in anatomy due to mispositioning and 
anatomical change of structures. In the context of this work, the selected deformation algorithm 
must also be efficient enough to be used while a mouse is under anesthesia and positioned on the 
machine for treatment.  
The BRAINSFit algorithm 
(http://www.slicer.org/slicerWiki/index.php/Modules:BRAINSFit) was chosen for registration of 
small animal CT images. This algorithm is an implementation of the B-spline algorithm available 
through Insight Tool Kit (http://www.itk.org/), a popular open source library of image 
registration tools.  The BRAINSFit implementation of the B-spline algorithm uses a mutual 
information-based cost function with a gradient descent optimizer. The BRAINSFit algorithm 
was selected for testing for the following features: 
1. Modeling of soft-tissue flexibility and elasticity due to elastic deformations 
2. The inherent smoothness and regularity of b-spline deformations when compared to 
Demon’s deformations [29] 
3. Mutual information’s utility for registering images of different modalities and 
applicability to different severities of deformation [31] 
4. The established accuracy of the ITK B-spline implementations using mutual 
information in pre-clinical imaging [31], [32], [33], [34], [35]  
5. The ability to control the scale of the deformation by changing the grid size 
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In order to use deformable registration to compare pre-clinical PET images, it is 
important to ensure that the selected algorithm can produce results with sufficiently small 
errors. For the purposes of this research, algorithmic errors must be small enough for two 
applications: 
1. For the comparison of two different PET images, the algorithm must be accurate to 
within the inherent PET resolution of 1.5 mm 
2. For treatment planning of small (approximately 3 to 5 mm) sub-volume dose escalations, 
the algorithm must display errors smaller than the size of the intended escalation 
The stricter requirement of registration errors being less than 1.5 mm was used as the 
benchmark for a good algorithm. Not only should the algorithm be accurate but it must also be 
capable of performing registration in soft-tissue regions with few visible landmarks. Previous 
validation studies have focused on well-defined landmarks or areas of specific anatomical 
structures [31], [32], [33], [34], [35]. Within tumors, however, there is usually very limited soft 
tissue contrast In order to successfully use deformable registration to recover the proper 
biological distributions of PET tracer, the algorithm must be capable of accurate registration 
even in these less distinct areas. In order to evaluate the performance of these algorithms in low 
contrast regions, landmarks must be introduced to these regions without affecting the 
performance of the algorithm. The following methods and materials discuss this process. 
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2.4. Methods and Materials 
2.4.1. Tumor model 
Nude mice inoculated with human tumor xenografts were used for the measurement of the 
errors in deformable registration algorithms. Tumors were implanted on the left and right flank 
of the mice and averaged 1 cm in the longest dimension. Prior to the implantation of any object 
within the tumors, the animals were sacrificed. All Imaging procedures were performed as 
quickly as possible to assure that rigor mortis had not set in during positioning of the sacrificed 
mouse on the scanner. 
2.4.2. Marker implantation 
One of the difficulties evaluating algorithms for registering tumors with CT anatomy is that 
the performance of the algorithm within the tumor is difficult to evaluate. Tumors contain no 
internal landmarks on CT scan for the algorithms to use for registering the images; there are also 
no landmarks with which to verify accuracy. In order to validate the ability of different 
deformable registration algorithms to generate proper deformation vector fields (DVFs) inside 
these tumors, landmarks had to be introduced into the tumor for the purposes of measuring 
registration errors. 
The landmarks used as fiducials in this work were selected from a large number of different 
materials. As the primary purpose of these markers is to provide contrast against soft tissue, the 
ideal marker should have an effective Z higher than 6, the approximate effective Z of soft tissue. 
However, high Z materials can be excessively attenuating at lower diagnostic imaging energies. 
In the case for small animal studies, images as low as 65 kV are used for imaging. At these lower 
energies the problems of marker artifact are exacerbated greatly compared to normal human 
imaging. A set of pilot studies was carried out to determine a material that produced good 
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contrast with soft tissue but did not create large density-related artifacts. In order for the marker 
to be visible on CT but leave minimal artifact, the ideal effective Z of the material should not 
only be greater than that of soft tissue but also less than that of bone, approximately 20. For these 
pilot studies, varying gauges of Aluminum (Z = 13), Copper (Z = 29) and stainless steel (Zeff  
Ziron = 26) were implanted into phantoms comprised of beef to qualitatively assess the artifacts 
induced by the marker. Copper and stainless steel were used, despite their high Z, because 
incredibly thin gauge (sub millimeter) wires were available and were still somewhat rigid 
compared to the aluminum alternatives. It was hypothesized that these thin gauge wires would 
not be excessively attenuating because of their small diameter, despite their high density. Figure 
9 shows the results of one imaging these different markers in a slab of beef. 
 
 
 
Figure 9: A 28 gauge steel marker (circled in red) shown on a CT of a phantom causing little artifact 
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A thin gauge composite copper magnet wire (diameter < 0.321 mm) was determined to give 
the best contrast with soft tissue with an acceptably small amount of metal artifact in the images. 
Further details on the selection of appropriate marker material can be found in Appendix I. After 
the best marker in the beef phantom images was determined a similar experiment was conducted 
using a sacrificed mouse to verify the marker’s performance in the small animal tumor model. 
After selecting the marker, sacrificed mice bearing subcutaneous xenografts were implanted with 
three pre-constructed markers of approximately 3 mm in length. Implantation was done using a 
modified pre-loaded 25 gauge needle with a 28 gauge steel obdurator threaded through the 
needle. Once implanted, the markers create a landmark on CT images inside the tumor. The thin 
gauge of the wire allowed the markers to be imaged without leaving extreme image artifacts 
(Figure 10).  
 
 
 
 
     Figure 10: CT image of a sacrificed mouse with implanted metal markers (shown in red circles) 
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2.4.3. Small animal PET imaging 
In order to compare the position of the markers, CT images were acquired using a Siemens 
Inveon small animal PET/CT/SPECT. Each mouse was positioned feet-first, prone on an animal 
specific pad (Figure 11) and imaged for 5 minutes. Animals were imaged at .5 mA and 75 kV as 
described in the protocol for all of our small animal experiments. The animal’s body was 
contoured and the tumors were marked on the pad for purposes of repositioning.  After imaging, 
the mouse was removed from the scanner and repositioned on the animal specific pad. As the 
mouse had already been sacrificed, the subcutaneous tumor could be intentionally subjected to 
mispositioning and deformation prior to re-imaging. The animals were then imaged a second 
time with the same imaging protocol. 
2.4.4. Image post-processing to remove markers 
 
CT images were segmented in Slicer 3D, an open source environment for medical image 
analysis. All markers were manually contoured using the slicer 3D segmenting tools. In order to 
achieve an unbiased image registration, the CT markers were removed using post processing 
 
Figure 11: An animal specific pad used for repositioning 
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Figure 12: TOP: The histogram of a large region of normal tumor tissue on CT (Left) and the histogram of values used to replace the CT 
marker randomly selected from the normal tissue ROI histogram (right).  BOTTOM: a CT image containing an implanted marker (Left) and the same 
CT image after post-processing to remover the marker (Right). 
 
prior to deformable registration. In order to facilitate the marker removal, large ROIs of tumor 
tissue were contoured in areas of the tumor containing no marker or artifact. The contours and 
images were then imported into MATLAB where the ROIs were used to generate a histogram of 
pixel intensities representative of tumor tissue free from artifact or marker. Values were then 
selected from the markerless tumor tissue histogram and used to overwrite the image intensities 
within the contour of the marker. The histogram for the new marker-free images was then 
compared against the markerless tumor histogram to ensure that the post-processed image did 
not contain any artifacts prior to saving the post-processed images for deformation (Figure 12) 
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2.4.5. Deformable Image registration and registration parameters 
 
Prior to image registration there were multiple parameters which needed to be optimized in 
order to achieve a successful image registration. In order to ensure the process was unbiased, 
region of interest options used for image registration were set to the auto-generate option, which 
contours the body of the animal using the greyscale contrast between the image background and 
the surface of the animal. Since the density of soft tissue remains constant between both imaging 
sessions, the histogram matching options were also used to improve the registration between the 
two CT images. The different initialization options available in slicer were examined to 
determine their utility in small animal CT-to-CT registrations. The non-manual registration 
options in slicer failed because the Inveon PET/CT and the SARRP have different fields of view 
which limit the extent of the animal shown in each image set. Since the extent of the animal 
imaged is different in each image set, initialization measures which are derived from anatomical 
geometry like center of mass measurements will not provide good initialization As a result, 
manual rigid initialization was used prior to all registrations. The two main parameters tested to 
ensure the best registration were the grid size and the number of samples. Selection of a grid size 
determines the number of control points on the image for use in deformation. The control points 
for this b-spline algorithm are uniformly spaced and define the points at which the hypothetical 
forces deforming the image are acting. Typically the more grid points introduced the more fine, 
local deformations are employed. This can lead to irregular transform causing unnatural 
transformed images. The fewer grid points used, the more global the deformation. The program 
guidelines suggest a starting grid size sub-dividing the image set into 14, 10, 12 segments 
respectively. In order to determine a suitable grid size for these deformations various grid sizes 
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were used to deform markerless images. Figure 13 shows the results of applying grid sizes of 
[14, 10, 12], [10, 6, 8] and [18, 14, 16].  
 
The smaller grid subdivisions seemed to align the marker reasonably but overall bony alignment 
suffered. The larger grid subdivisions performed well on the bony anatomy but registration of 
smaller structures like the markers suffered. The suggested default of 14, 10, and 12 seemed to 
provide a good middle ground between bony structure registration and marker registration. 
Ultimately the default grid size of 14, 10, and 12 was used as it produced the most successful 
deformations. 
 In addition to the grid size used for deformation, the number of samples is also an 
important determining factor to how well the deformation performs. The number of samples 
determines the number of voxels for which the mutual information between the two images is 
 
Figure 13: An overlay of deformed image (blue) and the fixed image (red) showing the effects of changing grid sizes of  [10,6,8] (left) , 
[14,10, 12] (center) and [18,14,16] (right) 
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compared. In other words, the number of samples selected directly affects both the global 
accuracy and the time required for computation. Slicer recommends a default value of 100,000 
samples. The images used in the deformations were 384 x 256 x 256 and 256 x 256 x 256, 
implying that there were 16,777,216 voxels in the smaller of the two images. While 100,000 
samples seem low when compared to the total number of voxels, the speed of the deformation is 
critical for the application of the algorithm to a small animal model where deformation must be 
performed while the animal is anesthetized. The time required for deformation for sample sizes 
ranging from 50,000 samples to 1,000,000 samples was recorded and the deformation errors 
were quantified. Figure 14 shows the effects of sample sizes of 100,000, 50, 000 and 1,000,000 
on the quality of the deformations.  
The suggested 100,000 sampling points gave acceptable registrations of both the markers 
and the bony anatomy in 2.6 minutes. Using fewer sampling points (50,000) reduced registration 
time to 51.34 seconds but the bony anatomy accuracy and the accuracy of the marker registration 
suffered. Increasing the number of sampling points to 1,000,000 increased computational time 
 
Figure 14: Overlay of deformed image (blue) and the fixed image (red) depicting the effect of changing the number of samples 
from 50,000 (left) to 100,000 (middle) to 1,000,000 (right) 
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significantly to 15.1 minutes and did not show a noticeable improvement in registration quality. 
For the purposes of image registration while the animal is anesthetized on the SARRP, a sample 
size of 100,000 was well within the 1.5 mm desired accuracy and was faster than 5 minutes.  
After determining a suitable set of parameters for image registration, the post-processed 
marker-free CT images were used as input into the registration algorithm. By using these images, 
the B-spline transform is free of the influence of the implanted markers. The unbiased B-spline 
transform can then be applied to the original moving image containing the markers. Using this 
methodology, the images containing markers can be registered to one another without the 
registration being driven by the presence of the markers (Figure 15). 
 
   
 
 
 
 
 
2.4.6. Analysis of marker displacements 
After image registration, the images containing markers were imported into Slicer 3D. The 
images were overlaid with one another and set to different color maps to allow for easier 
analysis. In order to ascertain the error inside the tumor, the maximum displacement between the 
marker borders was determined by evaluating the displacement in fractions of pixels using slicer 
3D measurement features and then multiplying by the pixel size to convert to an approximate 
distance (Figure 16). In this way, the largest displacement in millimeters was determined for the 
XY, YZ, and XZ planes were determined for each marker.  
 
Figure 15: the difference in CT images from day 1 (A.), day 2 (B.) and the deformed day 2 image (C.). The green contour 
represents the second day’s body contour and the purple represents the first day’s body contour. 
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2.5. Results 
The errors in transformations produced by the BRAINSFit implementation of the ITK B-
spline algorithm in Slicer 3D were smaller than the resolution of PET and allowed for an 
objective image registration. The measurement of the differences in marker position for the 
BRAINSFit yielded maximum displacements in any plane below 2 CT voxels or 0.67 mm 
(Figure 17). 
 
Figure 16: Axial (left), sagittal (middle), and coronal (right) planar displacements for a single marker 
 
 
Figure 17: Figure 16: Axial (left), sagittal (middle), and coronal (right) planar displacements for a single marker 
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This is well below the nominal small animal PET voxel resolution of approximately 1.5 mm. 
61 percent of all markers in the Slicer analysis were aligned with a maximum error of less than 
one CT voxel (0.335 mm) and 90 percent of all markers were aligned within 1.5 CT voxels 
(0.5025 mm).  
2.5.1. Error Analysis 
2.5.1.1.  Contouring and displacement measurement errors 
In order to ensure the error in marker registration was sufficiently small, errors associated 
with measuring the marker displacement were also analyzed. In order to determine the observer 
contouring error, the same sets of markers were blindly contoured multiple times and the 
reproducibility analyzed. In a similar manner, a single observer used the Slicer 3D measurement 
tools to estimate displacement for a single marker multiple times and the error was determined. 
Due to the incredibly small size of the markers, less than two voxels in the largest dimension, the 
contouring of the markers was done with a 1 pixel brush and was very reproducible. The marker 
size, however, was under two voxels in the largest dimension. As such, the 1 pixel brush was 
only capable of estimating the marker location within .37 mm. The final displacement of the 
markers was performed by using the measurement tools in Slicer 3D to assess the marker 
differences manually. Repeated measurements of markers yielded maximum measurement 
deviation of .03378 mm and an average variance of .000188 mm showing good reproducibility.  
2.5.1.2. Analysis of B-spline transformations 
To further validate that the marker registration process was being carried out properly, the 
transforms in the vicinity of the markers was analyzed. If the markers are properly masked there 
should be reduced deformation in the area of the markers. In order to verify this visually, B-
spline deformable transforms were generated registering two images containing markers and the 
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same two images without markers. The transforms were then applied to a 3D binary grid to see 
the effect of the transforms. Figure 18 shows the overlays of the two transformed grids overlaid 
with the transformed images and a comparison image between the two transformed grids.  
 
Given the size of the grids for deformation the markers are hypothesized to have little 
effect on the image. Upon inspection of the transforms there was little difference between the 
marker and markerless transforms. The transform produced with the markers present showed 
slightly more deformation in the area of the tumor. This supports the idea that the markers have 
been removed as there is less deformation in the area of the tumor when the markers are 
removed. Additionally any problems with marker removal are mitigated by the fact that a sparse 
grid is used.  
 
 
Figure 18: Image showing the effect of the markers on the B-spline transform.  The markerless transform is 
shown in blue (left), the marker-driven transform is shown in red (middle) and an overlay of the two transforms (right). 
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2.6. Conclusions 
 
The combined error of the B-spline transformations and measurements of marker deviation 
was shown to be well below the inherent PET resolution of 1.5 mm. Given these results, the 
Slicer3D’s BRAINSFit deformation algorithm was determined to be acceptable for use in small 
animal CT-CT image registration. In addition, two PET/CT data sets can be deformably 
registered by registering the accompanying CT images with the Slicer BRAINSFit package and 
applying the transforms to the PET image. As the errors in registration accuracy are smaller than 
resolution of the PET image, errors in the PET image will be sub-voxel and should not have a 
detrimental effect on data analysis of two registered PET images. 
  
35 
 
 
Chapter 3: In-vivo analysis of the spatial distributions of 18F-FDG and 18F-
FLT 
3.1. Background 
FDG PET imaging is used clinically to evaluate nodal involvement for tumor staging and 
grading. Due to the possibility of FDG uptake in areas of inflammation and the desire to target 
halmarks of increased tumor aggression, it has been suggested that other novel PET tracers could 
be useful in radiation oncology. Fluorothymidine (FLT), a tracer of cell proliferation, is one of 
many novel PET tracers that have been suggested as a potential clinical tracer for PET imaging. 
This chapter discusses the previous attempts at validating novel PET tracers and the need for the 
validation of the spatial distribution of novel PET tracers. FLT is compared to FDG to illustrate 
the efficacy of the proposed methodologies. 
 FLT was introduced to the clinic as a drug for HIV treatment; however the necessary 
concentrations of the drug proved to be toxic. Shields et al. conceptualized the use of  a smaller, 
non-toxic concentration of the compound tagged with radioactive flourine-18 for use as a novel 
PET tracer of proliferation [36]. FLT is structurally similary to thymidine but lacks one of the 
hydroxyl groups nessecary for full integration into DNA. As it is not a direct analogue of 
thymidine it becomes trapped within cells after phosphorylation by thymidine kinase one (TK1). 
The level of TK1 present in a cell is proportional to the phase of the cell cycle a cell is currently 
in with the highest concentrations of TK1 present during proliferation [36]. Given the 
relationship between FLT and TK1, and the relationship between TK1 and cellular proliferation, 
an increase in FLT uptake has been demonstrated to correlate with increased proliferation [36], 
[37].  
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In 2002 Toyohara et al. published their validation of FLT as a marker of cell proliferatin. 22 
cell cultures of different tumor cell lines were exposed to FLT for 60 minutes. After the uptake 
period cells were removed from the FLT solution. Liquid scintillators were then used to acquire 
counts for FLT uptake of each sample. Flow cytometry was used to determine the stage of the 
cells in each culture. A correlation analysis was then performed between the FLT uptake and 
number of cells in S-phase of the cell cycle. Toyohara found that FLT uptake showed a strong 
positive correlation with the total number of cells in S-phase [38]. 
Muzi et al. carried out an in-vivo kinetic analysis of FLT uptake in lung cancer in 2005. 
Patients were imaged sequentially using FLT PET over a period of 120 minutes in order to 
acquire FLT uptake at different time points. In addition to PET imaging performed at multiple 
time points, the ammount of radiotracer in the blood was assayed by venous blood sampling 
throughout the same 120 minute period. After imaging, specimens were ressected and mounted 
for immunoflourescene staining and histological analysis. Specimens were stained for Ki-67, a 
cell proliferation index. Standardized uptake value or SUV was used to characterize the uptake 
of FLT within the tumor at each time point. SUV  was calculated as the normalization of activity 
in the tumor to the injcted dose and the patients body weight. The fluctuation of FLT levels in 
the blood was also determined for different time points using blood sampling assays performed. 
Muzi then correlated the change in levels of FLT in the bloodstream to both Ki-67 index and 
FLT SUV. In addition, FLT SUV was also compared to Ki-67 index for each patient as well. 
Muzi et al. reported an incredibly strong spearman rank correlation of .92 between FLT SUV and 
fKi-67 labeling index and concluded that FLT was preferentially uptaken in proliferating tissues 
[39]. 
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In 2010, Troost et al. carried out a histopathologic validation of FLT. Seventeen patients with 
oral cavity carcinoma were imaged using FLT PET following a 60 minute tracer uptake period. 
After imaging, tumors were resected for histological analysis. PET images were normalized to 
the injected tumor activity and the patient body weight. Troost et al. looked specifically at the 
maximum and mean SUV values within the tumor. Prior to aurgical ressection of the tumor, 
iododeoxyuridine was injected intravenously. Three different blocks of each tumor were 
mounted for sectioning. After sectioning, tumors were stained for iododeoxyuridine, Ki-67 and 
TK-1 expression. TK-1 images were visually assesed by two researchers blinded to the PET 
results. Statistical correlation analysis of SUV maximum, mean, TK-1 expression, Ki-67 index 
and iododeoxyuridine staining was performed. Troost concluded that FLT could be a useful tool 
in patient response monitoring to therapy but required further validation before clinical use [40]. 
Zhang et al. published a pre-clinical analysis of FLT uptake in xenograft tumor models in 
2012. FLT micro PET/CT was performed after a tracer uptake period between 60 and 80 
minutes. In addition, Bromodeoxyuridine (BrdU), an extreinsic marker of cell proliferation for 
histological analysis was injected. FLT PET SUV values were then compared to BrdU, Ki-67 
and TK-1 staining of sectioned tumors. Zhang saw a positive correlation between FLT SUV and 
[
3
H] thymidine. While Zhang saw an agreement between TK-1 expression and FLT uptake, not 
all cells expressing increased TK-1 levels exhibited increased FLT uptake. Ultimately, Zhang 
concluded that FLT could be a useful clinical tool but would require more careful validation 
[41]. 
Since the original publications by Shields et al. FLT, has been thouroughly validated as a 
tracer of proliferation using ex-vivo, in-vivo and histological analyses. It has been shown, 
however, that FLT alone may not be sufficient as a stand-alone tracer for PET imaging due to its 
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low uptake compared to FDG [14], [42], [43]. The exception to this occurs in brain lesions where 
FDG does not perform well [44]. In general, it has been suggested that FLT’s primary use may 
be as a tracer for use in conjunction with the information provided by FDG [45], [46], [47]. 
Specifically, it has been suggested that FLT and other novel PET tracers can be used to treat 
underlying features of tumor biology. Prior to attempting multiple-tracer image guidance of 
radiotherapy it is important that the tracers are thouroughly compared to one another. 
In 2004, van Waarde et  al performed a study using FLT to distinguish between clinical 
disease and inflammation in a small animal model. Animals were inoculated with a subcutaneous 
flank xenograft and inflammation was also induced using an injection of turpentine. After 
establishing the tumor and inducing inflammtion, animals were imaged using FDG and FLT. 
Visual comparison and comparison of SUV values of both image sets were performed. 
Ultimately Van Waarde reported better contrast between normal tissues and high uptake regions 
for FDG PET images. FLT, however, did not show evidence of inflammation that was present in 
the FDG images [43]. 
In 2005, van Westreenen carried out a comparative study of FDG and FLT uptakes in ten 
patients with esophogeal cancer. FDG was allowed a 90 minute uptake period and FLT was 
allowed a 60 minute uptake period prior to scanning. After imaging, tumors were ressected and 
sectioned. Sectioned tumors were stained with Hematoxylin and eosin (H&E) for mophologic 
features and with Ki-67 for cell proliferation. The mean and maximum SUV values were 
calculated for both tracers and compared to the histological analysis. Van Westreenen observed 
that FDG was able to detect all primary cancers while FLT alone missed two of the ten cases. 
Quantitatively, the max and mean SUV values between FDG and FLT were used to compare the 
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two tracers. Van Westreenen concluded that FLT was not suitable to be used as a stand alone 
tracer in the clinic [48]. 
Also in 2005, Chen et al. examined the differences between FLT and FDG for use in 
gliomas. Twenty five patients were initially imaged with FDG and then imaged again with FLT 
on the following day. All scans were dynamic PET scans acquired over a period of 30 minutes. 
In addition to PET imaging, specimens were resected and stained for Ki-67.  For the purposes of 
analysis, PET images acquired over the 30 minute timeframe were summed and the mean SUV 
of the highest 20% of voxels and SUV max were calculated. FLT and FDG SUV values were 
compared using wilcoxon statistical test and were also compared with Ki-67 labelling indices. 
Ultimately Chen concluded that FLT was a more suitable clinical tracer for high-grade gliomas. 
Herrmann et al. conducted a very similar study of patients with gastric cancers in which very 
similar results were observed. FLT was shown to be more sensitive that FDG for gastric tumors 
[49]. 
Hoshikawa et al. carried out a comparison of FDG and FLT in 43 head and neck cancer 
patients in 2011. In a procedure similar to the previously described methods, patients were 
imaged using FDG and FLT PET on back to back days. The mean and maximum SUV values 
were calculated for both tracers. Hoshikawa found that the contrast between normal tissues and 
disease was better in FDG images than in FLT images. Quantitative analysis between FDG, FLT 
and sectioned tumors stained for Ki-67 was performed using the mean and maximum SUV 
values. From the analysis Hosikawa concluded that FLT was as sensitive as FDG for head and 
neck cancers [50]. 
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While all of these studies have compared the efficacy of FDG and FLT at segmenting tumor 
volumes, the only major quantitative comparison has been through mean and maximum SUV 
values. All of the aforementioned approaches neglect the spatial distributions of the two tracers 
in favor of assigning tumors a single numerical quantifier. While this approach can validate the 
ability of FLT to discern between FDG uptake in tumors and in areas of inflammation it is 
insufficient validation for using multiple tracers to plan therapy treatments. Despite the 
biological uptake mechanisms of novel PET tracers, poor vascularization and areas of necrosis 
limit the availability of the tracer to the tumor and have an equal effect on all PET tracers. The 
effects of these features could potentially overshadow the mechanisms of biological uptake and 
force both tracer distributions to be similar. To this end it is important to determine that a novel 
PET tracer contributes additional information to the information gained through FDG PET 
imaging. As previously mentioned, the effects of mispositioning and anatomical changes 
confound the ability to compare tracer distributions. Bowen et al. have attempted to circumvent 
this by analyzing only spontaneous canine tumors of the nasal cavity [bowen]. These tumors are 
largely rigid and do not deform between imaging sessions leading only to rigid translations. This 
does not mimic most clinical cases in which internal structures can shift and deform on a daily 
basis. In order to circumvent the confounding effects of deformations between imaging sessions, 
sequential scans performed over two separate days can be deformably resgistered and analyzed 
to determine the value of FLT as a tracer to be used with FDG in a small animal model.  
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3.2. Methods and Materials 
3.2.1. Establishing tumor lines 
Human head and neck tumor xenografts were used for the imaging and comparison of in-
vivo PET tracer spatial distributions. Nude mice were inoculated with FaDu or SQ20B tumor 
cells in the left and right shoulders. Xenografts were allowed to grow for 25 days on average 
prior to imaging. Two tumor lines, FaDu and SQ20B were used in order to compare the effect of 
two vastly different tumor morphologies on tracer distribution. FaDu tumors tend to be fast 
growing and exhibit large necrotic cores. The FaDu tumor line also exhibits very 
compartmentalized biological features with defined regions of hypoxia and proliferation. In 
contrast, SQ20B tumors tend to exhibit a slower growth and the biological features are more 
difficult to define (Figure 19) 
3.2.2. Small animal imaging 
Each animal was fasted for 6 hours prior to FDG imaging to simulate clinical protocol. 
Animals were allowed a 60 minute tracer uptake period prior to imaging. The animals were 
 
Figure 19: Immunofluorescence images of an SQ20B tumor (Left) and a FaDu tumor (Right) showing the differences in the 
distribution of hypoxia (red) and increased cell proliferation (green). 
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maintained under 3% isoflurane anesthetizia  during the uptake period to prevent FDG 
accumulation in active muscle groups. After uptake, each mouse was situated on an animal 
specific pad marked with the body contour and tumor locations (Figure 11). 
  Images were acquired using a Siemens Inveon dedicated small animal PET/CT/SPECT 
scanner. PET images were acquired for 10 minutes and the accompanying CT images were 
acquired for 5 minutes at .5 mA and 75 kV. The following day, animals were fasted again for 6 
hours to simulate the same conditions under which animals were previously imaged. Animals 
were injected with FLT and allowed the same 60 minute uptake period under 3% isoflurane 
despite FLT uptake being unaffected by active muscle groups. The animal was repositioned on 
the animal specific pad and imaged using the same protocols as the previous day.    
3.2.3. Deformable registration of FDG and FLT images 
After image acquisition, images were imported into the Slicer 3D for image registration and 
analysis. The PET images cannot be used as the inputs for the deformation as this would bias the 
results and force the FLT PET to mimic the FDG PET rather than preserving the biological tracer 
distribution. In order to achieve a registration that alleviates errors caused by mispositioning and 
anatomical changes while preserving the integrity of the true tracer distribution, the CT anatomy 
was used to generate a deformable registration transform. The CT accompanying the FLT PET 
image (moving image) was registered to the CT of the FDG data set (fixed image) using the 
BRAINSFit B-spline implementation in the Slicer package. As described in the registration 
protocol, no automatic image set initialization was allowed in Slicer registration and all contours 
used as inputs to the algorithm were generated automatically through the auto-generate ROI 
option. All images were initialized manually prior to registration to ensure the overlap of the 
images in the SARRP CT coordinate system. All tumor contours used for analysis were 
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manually contoured on the original fixed CT image set. The B-spline transform generated by 
deforming the moving image set was then applied to the FLT PET image to achieve an unbiased 
and objective registration of the FLT and FDG PET images. 
3.2.4. Voxel-by-voxel tracer analysis 
A voxel-by-voxel analysis of PET image sets was performed to analyze the changes in FDG 
uptake with regards to changes in FLT uptake on a voxel-by-voxel scale. All image sets and 
manual contours were imported into matlab. The tumor contours were used to mask out all non-
tumor data voxels during analysis. FDG and FLT intensities for each voxel were plotted on a 
scatterplot. Additionally the values were also binned by FLT intensity and an average value was 
calculated for each bin to visualize the trends in the data (Figure 20). 
. 
 
 
 
Figure 20: Binned and scatterplot representations of the correlation between FLT and FDG on a voxel-by-voxel basis in a FaDu tumor model 
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The Pearson correlation coefficient, rho, was also calculated for each data set and is defined 
as: 
cov( , )
x y
X Y

 
  
Where cov(X,Y) is the covariance of the FDG and FLT voxel intensities and sigma x and 
sigma y are the standard deviations foreach data set respectively. The Pearson correlation 
coefficient is a statistical test measuring the similarity between two data sets assumed to be 
Gaussian data sets sharing similar means. The values of rho range from -1 to 1 with perfectly 
correlated data showing a 1 and perfectly anti-correlated data showing a -1. This measure 
explores the differences in how the two tracers change with one another spatially but does not 
preserve the spatial information in the final correlation coefficient.  
3.2.5. Threshold-based tracer analysis 
In order to take a look at the spatial distribution of the tracers a threshold-based approach was 
used. FDG and FLT images were thresholded between 1 and 100% of maximum image intensity 
and intensity values below the threshold percentage of maximum were omitted. The Dice 
similarity coefficient was used to compare the overlap of the thresholded FDG volume with the 
thresholded FLT volume.  The Dice similarity coefficient is defined as: 
  
  ⋂  
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Where X and Y are the number of elements in each data set. The Dice similarity coefficient 
returns a value of 1 if the volumes are perfectly concordant and a value of 0 if the two volumes 
never overlap. These Dice ceofficients were tabulated for all threshold values between 1 and 
100% and a three dimensional “Dice surface” was created by plotting the values (Figure 21).
 
Figure 21: A "Dice similarity surface" created by varying FDG and FLT thresholds and plotting the Dice Coefficient 
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3.3. Results 
 
The Slicer 3 Analysis revealed a positive correlation between the uptake of FDG and FLT 
within the tumor for both tumor lines.  FaDu tumors exhibited a statistically significant average 
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correlation coefficient of r = .468 while SQ20B exhibited an average correlation coefficient of r 
= .704. The strength of correlation between FDG and FLT in FaDu and SQ20B tumors was 
statistically significant with a stronger correlation seen in the SQ20B tumors. This is likely due 
to the intermixed heterogeneous biology of the SQ20B cell line. There are typically no regions of 
interest within the tumor can be specifically selected as exclusively hypoxic or highly 
proliferating. Taking into account the inherent blur of the PET detector as well as biology, the 
FDG and FLT distributions appear more similar in the SQ20B images than in the FaDu images 
which exhibit a more compartmentalized geometry. 
 
 
 
 
 
 
 
 
Figure 22: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 13L 
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Figure 24: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 13R 
 
 
 
Figure 23: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 14L 
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Figure 26: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 14R 
 
 
Figure 25: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 16L 
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Figure 27: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 16R 
 
 
Figure 28: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 18L 
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Figure 29: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 18R 
 
 
Figure 30: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the FaDu tumor 13L 
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Figure 31: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the FaDu tumor 13R 
 
 
Figure 32: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the FaDu tumor 14L 
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Figure 33: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the FaDu tumor 14R 
 
Figure 34: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the SQ20B tumor 16L 
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Figure 35:  The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the SQ20B tumor 16R 
 
 
Figure 36: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the SQ20B tumor 18L 
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The Slicer 3 overlap analysis showed a lower overlap between the volumes at higher 
thresholds. At thresholds of 50% for both images, the high intensity regions overlap on average 
by 78% for FaDu and by 89% for SQ20B.  At 75% threshold for both images the overlap drops 
to only 47% for FaDu and 68% for SQ20B. If one were to begin thresholding FDG, it is obvious 
that the volumes of FDG and FLT diverge and at higher uptakes of FDG, FLT in some cases is 
an almost an entirely separate volume. This is likely due to the fact that FDG is specific to 
glucose metabolism which is upregulated in many different cells; hypoxic cells for example 
show an increased glucose metabolism.  
 
 
Figure 37: The scatterplot data binned and averaged by FLT intensity illustrating the change in FLT 
with FDG for the SQ20B tumor 18R 
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Figure 38: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for FaDu tumor 13L 
 
Figure 39: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for FaDu tumor 13R 
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Figure 40: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for FaDu tumor 14L 
 
Figure 41: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for FaDu tumor 14R 
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 Figure 42: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for SQ20B tumor 16L 
 
Figure 43: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for SQ20B tumor 16R 
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Figure 44: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for SQ20B tumor 18R 
 
 
Figure 45: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined 
by thresholding PET images at different percentages of maximum intensity for SQ20B tumor 18L 
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This data implies that the higher intensity FDG values are not indicative of proliferation but 
are more likely indicative of some other phenomenon, though the verification of this would 
require the same analysis with more tracers in future works. FaDu tumors also show more 
disagreement between FLT and FDG than the SQ20B tumor line. These results seem to agree 
logically with an analysis of the morphology of the two tumors. Histological analysis of the 
SQ20B tumor line exhibits a largely heterogeneous distribution of areas of small, intermixed 
hypoxic and proliferating cells. This would result in uptakes of FDG and FLT that would be 
largely concordant. The PET image resulting from these distributions would logically yield very 
similar images as the inherent resolution of the PET image would cause blurring and create two 
similar images. The FaDu images, on the other hand, show a greater difference between the two 
tracers. For FaDu tumors, the histology shows a much more compartmentalized model with areas 
of high proliferation being better defined and isolated from areas of hypoxia and normal cell 
metabolism. The resulting lower correlations in FaDu tumors supports the idea that FLT and 
FDG would be more encapsulated and less likely to uptaken in identical volumes despite the 
effect of large areas of necrosis forcing tracers into specific regions of the cell. This analysis 
implies that FDG and FLT do exhibit similar volumes but FLT yields additional spatial 
information that is not exhibited in FDG images. While these volumes may be small, in radiation 
oncology leaving any tumor cells untreated can be considered a failure of treatment.  
Clinically these results imply that FDG and FLT images could be acquired sequentially to 
gain additional insight into the microbiology of a tumor. The extent of additional information 
available is dependent on the tumor cell line with SQ20B tumors showing significantly more 
overlap of the FDG and FLT tumor volumes. The differences in overlap between FDG and FLT 
avid volumes determined by thresholding images above 50 percent of maximum imply that any 
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clinical approaches suggesting PET thresholding as a tool for tumor delineation should add 
additional margins to account for FLT avid regions not encompassed by FDG.  Additional spatial 
analysis will be required in the future to determine the extent of these margins. 
 In conclusion, FLT images yield additional useful information regarding the distribution of 
proliferating tumor cells. This becomes even more apparent when thresholding and auto-
segmentation of FDG images is used. In order to ensure treatment of these sub-volumes FLT 
should be considered for biological treatment planning assuming the introduction of a reliable 
clinical system for image registration of PET images. In addition, the inclusion of tracers of cell 
hypoxia in this same kind of analysis could yield to a better understanding of FDG tracer uptake 
in the tumor. 
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Chapter 4: PET imaging as an image guidance tool for placement of dose 
escalation for pre-clinical models 
 
Chapter 4 of this thesis provides the background literature review of PET’s role in treatment 
planning and discusses establishing a procedure for PET-guided selective radiation dose 
escalation in small animal tumor models. It is hypothesized that utilizing new small animal 
treatment technologies and deformable image registration it is possible carry out PET dose 
escalation on a small animal tumor models.  
4.1. Background 
Histological analysis of resected tumors has shown that underlying tumor biology is highly 
heterogeneous in nature and the radio-sensitivity of cells may vary across the tumor.  Advances 
in imaging techniques and the advent of novel PET tracers have facilitated non-invasive 
evaluation of this underlying biology for radiotherapy treatment planning. In 2000 Ling et al. 
proposed to use PET imaging as a non-invasive method for acquiring information about tumor 
microbiology [9]. Ling suggested that utilizing the spatial distributions of FDG, FLT and 
Fluoromisonidazole (F-MISO) and the CT-delineated gross tumor volume (GTV) that treatments 
could be individualized for each patient. The addition of PET images to the anatomical GTV 
would allow physicians to consider the radio-resistance of different areas of the tumor rather than 
the entire tumor as a single mass. 
Since the publications of Ling et al. in 2000, many studies have explored the feasibility of 
PET image guidance. In 2003, Tralins et al. carried out a clinical trial using PET, MRI and CT to 
guide dose escalations to 38 patients with glioblastoma multiforme brain tumors. Tralins defined 
the PET tumor volume as any area within the CT and MRI defined GTV with higher PET tracer 
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uptake than normal white matter outside the GTV. The comparison of the CT-, MRI- and PET 
derived tumor volumes revealed that high FDG uptake defined a volume which was 25% smaller 
than the volumes defined by MRI and CT Additionally Tralins et al. found that the uptake of 
FDG tracer was a predictor of treatment outcome [19].  
Schwartz et al. carried out an investigation of the potential role of FDG PET in head and 
neck cancer dose escalation in 2004. 20 patients with various head and neck cancers were 
imaged using a dedicated PET scanner and a separate dedicated CT scanner. After imaging, b-
spline deformable image registration was used to alleviate the effects of mispositioning. 
Schwartz et al. defined the PET-avid region, or GTV PET, as any area within the CT-contoured 
GTV exhibiting higher FDG uptake values than normal tissue. Only 5 patients underwent 
treatment in this study, receiving 66 Gy to gross disease in 30 fractions. The GTV PET was then 
escalated by repeatedly treating with 2.2 Gy fractions until a dose limiting normal tissue 
constraint was reached. Ultimately this study produced no results regarding improvement of 
tumor control or patient survival. Schwartz et al. did conclude that dose escalation up to doses of 
72.4 Gy were feasible for escalation of a PET GTV [18]. 
In a 2005 study of locally advanced non-small cell lung cancer patients, De Ruysscher et al. 
used a dedicated dual-modality PET/CT scanner to acquire intrinsically fused PET/CT image 
sets. These image sets were used to generate and compare treatment plans using CT information 
and plans using PET/CT information. De Ruysscher et al. concluded that PET-avid regions 
produced smaller treatment volumes than CT-contoured target volumes and as such could be 
treated to higher doses before normal tissue complications were observed [16]. Van Der Wel at 
al. also reported similar findings in their 2005 modeling of PET--contoured radiotherapy 
planning [17]. 
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All of these studies have produced results supporting the escalation of dose to sub-volumes 
of CT-defined GTV without compromising normal tissue. They all exclusively use FDG PET to 
delineate an active tumor volume within the GTV for treatment. As FDG images are 
representative of increased glucose metabolism they are typically used to define the entire tumor 
rather than radio resistance sub-volumes. As such, all of the presented studies neglect the 
heterogeneity of the underlying biological properties of the tumor. The goal of treatment 
planning for all of these studies was to deliver a homogeneous dose to the tumor volume as 
defined by PET. Dose escalation, in the context of these studies, refers to the researcher’s ability 
to treat the tumor to higher homogeneous doses while achieving the same organs at risk dose due 
to the smaller clinical target volumes as determined by PET. This differs greatly from the 
scenario proposed by Ling et al. in which the dose was escalated to regions of interest (ROI) 
throughout the entire tumor with the goal of treating specific cells to a dose determined by their 
respective radio-resistances. 
Vanderstraeten et al. proposed the concept of prescribing dose to individual voxels using the 
intensities in the PET image to determine dose. The intensity in each voxel of the PET image is 
directly related to the activity of FDG in each voxel at the time of imaging. This approach 
assumed a positive correlation between tracer uptake and radio-resistance. To this end, 
Vanderstraeten assigned higher doses to voxels with higher intensity relative to other voxels 
within the GTV. This approach became known as dose paint-by-numbers in contemporary 
research studies. In this study the dose paint-by-numbers approach was compared to a more 
conservative method in which the PET image was broken into regions of interest by binning 
voxels into discrete groups and prescribing dose to regions rather than voxels. Vanderstraeten 
ultimately concluded that their modeling of both voxel-defined and region of interest-defined 
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dose prescriptions showed no significant effect on the organ at risk doses. These results imply 
that the dose to the tumor can be redistributed to treat features of interest within the image 
preferentially without detrimental effect to the organs at risk. Vanderstraeten did, however, point 
out that in order to be able to improve local control it would be necessary to establish the 
relationship between PET tracer uptake and cell radio-sensitivity in a voxel [52]. 
Madani et al. carried out the first dose paint-by-numbers phase I clinical trial in 2007. 41 
patients were treated using the voxel-defined dose assignment method published by 
Vanderstraeten et al. to treat areas of higher PET uptake to higher doses and areas of lower PET 
uptake to reduced doses. Madani et al. reported an average patient one year survival rate of 
83.5%. In general, Madani concluded that PET dose escalation is achievable in patients. It is 
important to note, however, that Madani et al. did report a treatment-related death at higher dose 
levels. The specifics of this treatment related death were not disclosed in the paper [53]. 
Overall, research towards biologically-guided treatment has been slowly progressing towards 
the vision presented in the Ling’s 2000 publication. Still, there is little evidence supporting a 
relationship between increased FDG uptake on a PET image and increased radio-resistance 
within the tumor [52]. Aerts et al. argue that previously published studies have shown that FDG 
alone can provide a map of viable tumor cells. Aerts suggests that escalating dose to an FDG-
positive volume will deliver sufficient dose to increase cell kill in radio-resistant sub-populations 
without the need to explicitly identify them as radio-resistant [2]. Aerts’ suggested PET-guided 
treatments which assume that all glucose avid cells are radio-resistant are inefficient in the 
redistribution of delivered dose as FDG can be taken up in radio-sensitive cancer cells. 
Unilaterally escalating dose to the whole tumor will result in increased dose to these radio-
sensitive cells which do not require an escalated dose. The escalation of dose to areas of radio-
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sensitivity is unnecessary as these cells are rendered non-viable by original, non-escalated 
prescription dose. Selective dose escalation, or preferentially increasing dose only to regions of 
high radio-resistance or biological importance, would allow for a lower organ at risk dose in 
regions bordering radio-sensitive tumor cells. 
Due to the lack of data to support the co-localization of high FDG uptake and cells displaying 
increased radio-resistance and the subjectivity of defining high-uptake regions of interest it 
seems premature to proceed with selective dose escalation. It would be ideal to perform 
treatments on a small animal model in order to verify that PET-guided selective escalation confer 
a benefit in treatment outcome. Unfortunately, using currently available technology, it is not 
possible to perform intensity modulated radiotherapy (IMRT) treatment of small animal tumor 
models. However, it is possible to carry out the planning and delivery of CT image-guided 
selective radiation dose escalation of small animal tumor models using a dedicated CT-guided 
small animal irradiator such as  Small Animal Radiation Research Platform (SARRP) developed 
by Johns Hopkins University and Xstrahl.  
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4.2. Small Animal Radiation Research Platform 
 
The SARRP system allows for the precise delivery of radiation to a pre-clinical model. 
Precision irradiation is delivered using small-field (down to 1 x 1 mm) and the rotation of both 
the gantry-mounted x-ray tube and the animal treatment couch. The system is capable of 
delivering both static and dynamic beams with a static collimator system with a maximum dose 
rate of approximately 3.5 Gy per minute. In addition to irradiation capabilities for treatment, the 
SARRP is also capable of on-board cone-beam CT and portal imaging during treatment. These 
imaging techniques can be used to guide the delivery of radiation. CT images can be used for 
treatment planning while portal imaging can be used for online imaging. 
 
Figure 46: The SARRP (left) system comprised of a dual-filament x-ray tube (A), a collimating cone 
of 15 mm diameter (B), a rotating couch for the animal to be positioned on (C), a Perking Elmer flat panel 
detector for acquiring cone-beam CT images (D),  a robotic stage capable of shifting the couch in the X, Y, 
and Z directions (E) and the selection of static collimators (F) which range in size from 5 x 9 mm to 1 x 1 mm 
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The machine consists of a robotic stage and treatment couch which can shift in the X, Y 
and Z dimensions by approximately 50, 50 and 38 mm with a positional accuracy of .065 mm. 
The stage is also designed for rotation from -180 degrees to 180 degrees with a default position 
of 0 degrees and a rotational accuracy of .05 degrees. The gantry of the machine can be rotated 
from 0 degrees, completely vertical, to approximately 127 degrees. There are two imaging units 
on board the SARRP, a small CCD camera for portal imaging and minor fluoroscopic imaging as 
well as a flat panel cone-beam CT imaging detector. The x-ray tube can supply up to 225 kV x-
rays using a large 3mm focal spot and 13 mA of current for treatment. Using a smaller .4 mm 
focal spot, the system produces x-rays in the rage of 50 – 150 kV for imaging. The addition of a 
Perkins Elmer flat panel detector allows for cone-beam CT images to be acquired with the 
animal in treatment position (Figure 47) [54] .  
 
In order to acquire a CT image, the animal and treatment couch are rotated 360 degrees 
while the x-ray tube and flat-panel detector are kept stationary to acquire projections. Images are 
 
Figure 47: The SARRP in position for cone-beam CT imaging. The lead shield has been removed from the flat panel 
detectors, the gantry is rotated to 90 degrees and the collimating cone has been removed. 
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reconstructed in real-time and are made available to a proprietary treatment planning system. The 
images acquired on the SARRP can then be used to plan treatments to be delivered on the 
machine. The system in its current form does not employ the use of multi-leaf collimators but 
uses a system of static collimators that are manually fitted to a collimating cone. The 
uncollimated field of VCU’s SARRP system is approximately 30 x 30 mm. The collimating cone 
produces a 15 mm diameter circular field. The additional collimators range in size from a 5 x 5 
mm collimator to a 1 x 1 mm collimator. 
 For treatments employing the use of multiple beams, multiple collimators or arcs 
a SLICER 3D treatment planning system is used. This system uses a fast GPU superposition-
convolution algorithm that is detailed in a paper published by Jacques et al. from Johns Hopkins 
University [Jacques]. This algorithm allows for very quick dose distribution calculations, on the 
order of tens of seconds, for both static beam treatments and much more complicated coplanar 
and non-coplanar arc beam deliveries. The fast planning capabilities allow for planning to be 
completed while the animal is anesthetized on the treatment machine. The combination of this 
pre-clinical treatment planning system and the image-guided treatment delivery capabilities of 
the SARRP facilitate pre-clinical radiotherapy research.  
4.3. Methods and Materials 
4.3.1. Establishing tumor models and growth curves 
FaDu human head and neck tumor xenografts were subcutaneously implanted and used as 
targets for the delivered radiation therapy plans. Tumors were established by inoculating nude 
mice with .5 *10
6
 FaDu cells in the left and right shoulders. All animals maintained in 
compliance with the guidelines of Virginia Commonwealth University’s Institutional Animal 
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Care and Use Committee. Every two days the tumor size was measured using calipers and the 
volume was estimated using the formula for a prolate spheroid: 
2
arg* *
6
L e smallDiameter Diameter

 
In order to keep measurement errors systematic and prevent adding inter-observer variations, 
all caliper measurements were performed by the same researcher.  
4.3.2. Determining a suitable dose level 
 
Prior to studying the effect of sub-volume dose escalation, the effect of single homogeneous 
fractions needed to be observed in order to select a suitable dose level for observing the effects 
of treatments. There has been extensive research on the use of FaDu tumors for fractionated 
regiments citing 


 values of approximately 15 Gy for fractionated treatment regiments in 
xenograft models [56], [57], [58]. However, there are few studies delivering single fraction large 
doses to FaDu tumor xenografts. In order to evaluate the response of the FaDu tumors to large 
single dose fractions, tumor bearing nude mice were treated with single fraction doses of 20, 35, 
50 or 60 Gy. The non-coplanar arc capabilities of the SARRP allowed for the distribution of dose 
over a larger area of skin, preventing severe skin reactions. The flank tumor model also provided 
easy to access to the target tumor with no major critical structures to be concerned with.  
After treatment tumor growth was measured for up to 25 days by caliper. Single fraction 60 
Gy homogeneous deliveries showed almost complete regression of the tumor. An additional 
escalation of dose beyond 60 Gy would not produce observable results. Similarly, the 50 Gy 
treatments showed immediate tumor response which would not be useful in observing the 
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response of an additional dose escalation. The 35 Gy treatments showed a continued growth up 
to 5 days after treatment and then a significant reduction of the tumor volume. Single doses of 20 
Gy also showed statistically similar results to that of 35 Gy single fraction treatments. It is likely 
that he large effect of these single fraction doses would overshadow any potential benefits of the 
dose escalation. In light of the initial results a homogeneous dose of 10 Gy was also tested for 
efficacy. It was observed that 10 Gy dose was less effective in controlling tumor growth and 
seemed to provide a good baseline homogeneous dose for studying the effect of dose escalation 
(Figure 48).  
 
Figure 48: Tumor xenograft growth after treatments of 10, 20, 35, 50 and 60 Gy (normalized to day of treatment volume) 
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The differences between the effects of doses between 10 and 20 Gy led to the decision of 
using a homogeneous delivery of 10Gy and a small sub-volume escalation of another 10 Gy in 
order to view the effects of the dose escalation. Ideally this method would yield results 
somewhere between the 10 and 20 Gy single fraction treatments. 
4.3.3. Small animal FDG PET imaging 
On the 24th day after tumor implantation, the animals underwent the same PET/CT 
imaging procedures as described in the previous chapter. Each animal was fasted for 6 hours 
prior to tracer injection and imaging. A 60 minute tracer uptake period was allowed prior to 
scanning during which animals were anesthetized under 3% isoflurane. All animals were 
positioned on an animal specific pad on which body contours and tumors were marked for 
repositioning. The animals were imaged using CT at .5mA and 75 kV for 5 minutes and PET 
images were acquired for 10 minutes. After imaging, animals were allowed to recover and were 
fed normally.  
4.3.4. PET dose escalation  
The small animal PET/CT data sets acquired using the Inveon PET/CT scanner were 
imported into Slicer 3D (http://www.slicer.org/ ) and the tumors were manually contoured. After 
contouring, the image sets and contours were imported into Matlab where a custom script 
analyzed the PET image, comparing the uptake within spherical volumes, representative of the 
selected 5mm collimator, inside the tumor as defined by manual contouring. The average uptake 
was determined for every location of the 5mm sphere within the tumor and the sphere containing 
the highest FDG uptake was designated as the target for the dose escalation. A target PET image 
set was created by marking the center of the sphere of highest uptake with a pixel of zero 
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intensity. In this way, an animal specific selective dose escalation plan was made using only the 
FDG PET information (Figure 49). 
.  
 
 
4.3.5. Treatment delivery 
The day following the PET/CT imaging, the 25
th
 day since tumor implantation, animals 
were irradiated using the SARRP. Animals were anesthetized using ketamine-xylazine and were 
repositioned on the animal specific pad. The SARRP lasers were used to align the animals and 
the on board flat panel detector was used to acquire cone-beam CT projections of the animal at 1 
mA and 65 kV. After CT acquisition the images were opened in the SARRP graphical user 
interface (GUI) treatment planning plug-in and the delivery of homogeneous dose of 10 Gy was 
planned. A 15mm diameter circular collimator was positioned over the tumor to cover the entire 
 
Figure 49: Workflow of determining the volume of highest PET uptake. An example of a binary matrix 
representative of the collimators (Left) a figure showing a circular template scanned through the area of the tumor 
(middle) and a planned treatment targeting the volume of highest PET uptake (right) 
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tumor volume as defined by CT while avoiding internal structures. During the delivery of the 
homogeneous 10 Gy dose, the PET/CT image set used for planning had to be registered to the 
CT data acquired on the SARRP in order to alleviate the effects of mispositioning and 
anatomical changes (Figure 50).  
 
The BRAINSFit algorithm was chosen for the purpose of registering the planning CT to 
the SARRP CT because of the algorithm’s ability to handle small local PET deformations 
without introducing errors larger than 1.5 voxels. This algorithm is available in the Slicer 3D 
package used for treatment planning on the SARRP. The efficiency of this algorithm allowed for 
carrying out registration of the planning CT to the treatment position CT while the animal was 
 
Figure 50: The alignment between treatment CT (in red) and planning CT (in blue) before (left) and after 
image registration (right) 
 
75 
 
anesthetized. The only inputs that were required for registration were the planning and treatment 
position CT data sets. Registration of the images was initialized by means of manual rigid 
registration. The SARRP CT images were not normalized to Hounsfield units so in order to 
achieve the most accurate image registration histogram matching was used. The auto-ROI 
feature was used to generate the required ROIs for the registration and the ROIauto variables 
were set to .9mm for expansion and contraction of structure contour borders for small animal 
images instead of the 9mm used for human images. The transform produced by registering the 
planning CT to the SARRP CT was then applied to the planning PET image. In this way the PET 
image is registered with the SARRP CT from the treatment day and the offset isocenter for dose 
escalation can be placed over the area of highest PET uptake. Using non-coplanar arc delivery a 
5mm approximately spherical dose of 10 Gy was then delivered to the selected sub-volume of 
the tumor.  
 
4.3.6. Pilot study: PET dose escalation vs. arbitrary escalation 
In order to illustrate the use of the proposed methodology, a pilot study was carried out 
comparing PET- and CT-guided dose escalations. Animals were randomly assigned to one of the 
two cohorts. The CT-guided cohort received a 10 Gy irradiation to the entire tumor and an 
additional 10 Gy irradiation to a 5 mm, approximately spherical, volume at the center of the 
tumor placed using only CT anatomy. The PET-guided cohort received the same 10 Gy initial 
irradiation as the previous cohort and a 10 Gy escalation to a 5mm sub-volume defined by the 
region of the highest FDG uptake within the tumor. A control cohort receiving no radiation was 
previously established for purposes of analysis and comparison. The measured change in tumor 
size was used as a surrogate for the ability of each treatment to control tumor growth (Figure 51). 
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4.3.7. Post-treatment tumor growth and analysis 
After treatment, the tumor growth was evaluated by caliper measurements. The animals were 
monitored for up to 50 days after treatment provided that the tumors did not grow beyond the 
limits established by VCU’s animal care policies and that the animal was not experiencing any 
weakness or discomfort.  The growth of the tumors was determined and the percent change in 
volume compared to the day of treatment volume was calculated and plotted (Figure 52). 
 
Figure 51: An arbitarary dose escalation of the center of a tumor (Left) and a dose escalation positioned on 
the volume of highest PET uptake (Right). 
 
Figure 52: The percent change in tumor volume in tumors treated with PET dose escalations (Pink) and center of tumor dose 
escalations (blue) 
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In order to assess the benefit of each treatment, the delay in tumor growth was used. The time 
necessary for the tumor to achieve an increase in volume of 25, 40 and 50 percent relative to its 
pre-regression size was recorded and compared between the two cohorts. 
4.4. Results  
The average time for a tumor treated with a PET-guided dose escalation to reach a 25, 40 
and 50% increase in tumor volume was 14 +/- 6.8, 16.2 +/- 5.1 and 16.7 +/- 5.4 days after initial 
treatment. The same times for escalations to the center of the tumor were 8.6 +/- 7.1, 11.3 +/- 7 
and 14.3 +/- 7.14 days after initial treatment. On average the PET-guided dose escalation delayed 
tumor growth by 2 to 6 days when compared with dose escalations to the geometric center of the 
tumor (53).  
Additionally, the PET-guided dose escalation controlled tumor growth so well in one 
tumor that an increase in volume of 25 % was never achieved in the 50 day observation period.  
 
Figure 53: The average time required for tumors treated with PET-guided escalation (left) and CT-guided escalation (right) to 
reach a 25, 40 and 50% increase in volume 
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In general, both the PET-targeted and Center-targeted treatments were successful in delaying 
tumor growth. However, the number of tumors in each arm, 5 for PET and 8 for center boosting 
respectively, was too few to establish a statistically significant benefit for the PET-guided 
methodology. 
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Chapter 5: DISCUSSION 
This thesis has set the ground work for the planning and delivery of PET-guided selective 
dose escalations for a pre-clinical research model. Additionally a pilot study was carried out 
comparing the efficacy of FDG -guided dose escalation with a dose escalation placed blindly in 
the geometric center of the tumor. While data from the trial was not statistically significant, the 
results of monitoring change in tumor volume implied a more favorable tumor control using the 
PET-guided methods. This method can be easily adapted for other PET tracers and other 
methods of image guidance using functional and anatomical imaging.  
Currently the SARRP treatment planning system only allows for manual forward planning 
which hinders the delivery planning of advanced techniques like dose paint-by-numbers. Ford et 
al. have shown that it is feasible to commission clinically available treatment planning software 
with inverse planning capabilities for use with the SARRP [59]. More advanced treatments 
would require extensive pre-planning and adapting of the pre-plan to the day of treatment 
anatomy. The imprecision of repositioning small animals for treatment would also confound the 
delivery of complicated plans. Introducing an isoflurane system to the SARRP would extend the 
time the animal remains anesthetized and could make planning these more complicated plans 
feasible without extensive pre-planning.  
Another potential limitation of this work includes the assessment of tumor growth using 
caliper measurements. If more precise measurements of tumor growth were required, any 
imaging technique could be used to acquire measurements of the tumor growth. There are 
drawbacks, however, to repeat imaging of small animal tumor models. In the case of CT, repeat 
imaging every over a month as a surrogate for physical measurement would result in a 
significant accumulation of dose to the animal which would confound the ability to gauge the 
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efficacy of treatments. In addition, while MRI would seem to be ideal for this scenario as it uses 
no ionizing radiation, it is also important to note that mice do not tolerate anesthesia well and 
repeatedly anesthetizing mice could severely weaken or even kill the animal.  
Despite limitations in the currently available technology, this research provides 
methodology for pre-clinical research of biologically-guided selective dose escalation treatments. 
In the near future there will be many upgrades available for the SARRP system including new 
imaging methodologies and dynamic collimator systems. This protocol can also be easily 
adapted to include the addition of other imaging modalities, multi-leaf collimator systems, and 
any other relevant improvements in the machine and software. Using this approach with one or 
more PET tracers, data for biologically-guided treatment could be amassed prior to moving to 
clinical trials, leading to more successful trials and a greater acceptance of biological-guidance in 
radiotherapy. 
  
81 
 
Bibliography 
[1] J. Bernier, E. J. Hall, and A. Giaccia, “Radiation oncology: a century of achievements,” 
Nat. Rev. Cancer, vol. 4, no. 9, pp. 737–747, Sep. 2004. 
[2] H. J. W. L. Aerts, P. Lambin, and D. D. Ruysscher, “FDG for dose painting: a rational 
choice,” Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 97, no. 2, pp. 163–164, 
Nov. 2010. 
[3] R. L. Bakst, N. Lee, D. G. Pfister, M. J. Zelefsky, M. A. Hunt, D. H. Kraus, and S. L. 
Wolden, “Hypofractionated dose-painting intensity modulated radiation therapy with 
chemotherapy for nasopharyngeal carcinoma: a prospective trial,” Int. J. Radiat. Oncol. 
Biol. Phys., vol. 80, no. 1, pp. 148–153, May 2011. 
[4] D. Pulte and H. Brenner, “Changes in survival in head and neck cancers in the late 20th and 
early 21st century: a period analysis,” Oncologist, vol. 15, no. 9, pp. 994–1001, 2010. 
[5] M. A. Deveau, S. R. Bowen, D. C. Westerly, and R. Jeraj, “Feasibility and sensitivity study 
of helical tomotherapy for dose painting plans,” Acta Oncol., vol. 49, no. 7, pp. 991–996, 
Oct. 2010. 
[6] S. M. Bentzen and V. Gregoire, “Molecular-imaging-based dose painting - a novel 
paradigm for radiation therapy prescription,” Semin. Radiat. Oncol., vol. 21, no. 2, pp. 101–
110, Apr. 2011. 
[7] A. Pugachev, S. Ruan, S. Carlin, S. M. Larson, J. Campa, C. C. Ling, and J. L. Humm, 
“Dependence of FDG uptake on tumor microenvironment,” Int. J. Radiat. Oncol. Biol. 
Phys., vol. 62, no. 2, pp. 545–553, Jun. 2005. 
[8] M. Axente, J. He, C. P. Bass, J. I. Hirsch, G. Sundaresan, J. Williamson, J. Zweit, and A. 
Pugachev, “Tumour microenvironment heterogeneity affects the perceived spatial 
concordance between the intratumoural patterns of cell proliferation and 18F-
fluorothymidine uptake,” Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 105, no. 
1, pp. 49–56, Oct. 2012. 
[9] C. C. Ling, J. Humm, S. Larson, H. Amols, Z. Fuks, S. Leibel, and J. A. Koutcher, 
“Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological 
conformality,” Int. J. Radiat. Oncol. Biol. Phys., vol. 47, no. 3, pp. 551–560, Jun. 2000. 
[10] A. Rahmim and H. Zaidi, “PET versus SPECT: strengths, limitations and challenges,” Nucl. 
Med. Commun., vol. 29, no. 3, pp. 193–207, Mar. 2008. 
[11] C. S. Levin and E. J. Hoffman, “Calculation of positron range and its effect on the 
fundamental limit of positron emission tomography system spatial resolution,” Phys. Med. 
Biol., vol. 44, no. 3, p. 781, Mar. 1999. 
[12] T. Barwick, B. Bencherif, J. M. Mountz, and N. Avril, “Molecular PET and PET/CT 
imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive 
evaluation,” Nucl. Med. Commun., vol. 30, no. 12, pp. 908–917, Dec. 2009. 
[13] K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. 
Schuster, H.-J. Wester, J. R. Siewert, M. Schwaiger, and B. J. Krause, “Imaging gastric 
cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis,” J. 
Nucl. Med. Off. Publ. Soc. Nucl. Med., vol. 48, no. 12, pp. 1945–1950, Dec. 2007. 
[14] S. M. Larson and H. Schoder, “New PET tracers for evaluation of solid tumor response to 
therapy,” Q. J. Nucl. Med. Mol. Imaging Off. Publ. Ital. Assoc. Nucl. Med. Aimn Int. Assoc. 
Radiopharm. Iar Sect. Soc. Radiopharm. Chem. Biol., vol. 53, no. 2, pp. 158–166, Apr. 
2009. 
82 
 
[15] K. A. Krohn, F. O’Sullivan, J. Crowley, J. F. Eary, H. M. Linden, J. M. Link, D. A. 
Mankoff, M. Muzi, J. G. Rajendran, A. M. Spence, and K. R. Swanson, “Challenges in 
clinical studies with multiple imaging probes,” Nucl. Med. Biol., vol. 34, no. 7, pp. 879–
885, Oct. 2007. 
[16] D. De Ruysscher, S. Wanders, A. Minken, A. Lumens, J. Schiffelers, C. Stultiens, S. 
Halders, L. Boersma, A. van Baardwijk, T. Verschueren, M. Hochstenbag, G. Snoep, B. 
Wouters, S. Nijsten, S. M. Bentzen, M. van Kroonenburgh, M. Ollers, and P. Lambin, 
“Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients 
with non-small cell lung cancer on dose limiting normal tissues and radiation dose-
escalation: a planning study,” Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 77, 
no. 1, pp. 5–10, Oct. 2005. 
[17] A. van Der Wel, S. Nijsten, M. Hochstenbag, R. Lamers, L. Boersma, R. Wanders, L. 
Lutgens, M. Zimny, S. M. Bentzen, B. Wouters, P. Lambin, and D. De Ruysscher, 
“Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage 
N2-N3M0 non-small-cell lung cancer: a modeling study,” Int. J. Radiat. Oncol. Biol. Phys., 
vol. 61, no. 3, pp. 649–655, Mar. 2005. 
[18] D. L. Schwartz, E. C. Ford, J. Rajendran, B. Yueh, M. D. Coltrera, J. Virgin, Y. Anzai, D. 
Haynor, B. Lewellen, D. Mattes, P. Kinahan, J. Meyer, M. Phillips, M. Leblanc, K. Krohn, 
J. Eary, and G. E. Laramore, “FDG-PET/CT-guided intensity modulated head and neck 
radiotherapy: a pilot investigation,” Head Neck, vol. 27, no. 6, pp. 478–487, Jun. 2005. 
[19] K. S. Tralins, J. G. Douglas, K. J. Stelzer, D. A. Mankoff, D. L. Silbergeld, R. C. 
Rostomily, S. Hummel, J. Scharnhorst, K. A. Krohn, A. M. Spence, and R. Rostomilly, 
“Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information 
and possible role in definition of target volumes in radiation dose escalation,” J. Nucl. Med. 
Off. Publ. Soc. Nucl. Med., vol. 43, no. 12, pp. 1667–1673, Dec. 2002. 
[20] D. A. Mankoff and F. Dehdashti, “Imaging Tumor Phenotype: 1 Plus 1 Is More Than 2,” J. 
Nucl. Med., vol. 50, no. 10, pp. 1567–1569, Oct. 2009. 
[21] V. Wyawahare, P. Patil, and H. Abhyankar, “Image Registration Techniques: An 
overview,” Int. J. Signal Process. Process., vol. 2, no. 3, Sep. 2009. 
[22] B. Zitová and J. Flusser, “Image registration methods: a survey,” Image Vis. Comput., vol. 
21, pp. 977–1000, 2003. 
[23] W. Crum, “Non-rigid image registration: theory and practice.,” Br. J. Radiol., vol. 77, pp. 
S140 – S153, 2004. 
[24] R. M. Kessler, J. R. Ellis Jr, and M. Eden, “Analysis of emission tomographic scan data: 
limitations imposed by resolution and background,” J. Comput. Assist. Tomogr., vol. 8, no. 
3, pp. 514–522, Jun. 1984. 
[25] M. R. Kaus, K. K. Brock, V. Pekar, L. A. Dawson, A. M. Nichol, and D. A. Jaffray, 
“Assessment of a Model-Based Deformable Image Registration Approach for Radiation 
Therapy Planning,” Int. J. Radiat. Oncol. Biol. Phys., vol. 68, no. 2, Jun. 2007. 
[26] L. Veugen, “Image Registration Techniques, Benchmarking, Strategy,” Brigham and 
Women’s Hospital, Boston, MA, Jul-2010. 
[27] J. P. Thirion, “Image matching as a diffusion process: an analogy with Maxwell’s demons,” 
Med. Image Anal., vol. 2, no. 3, pp. 243–260, Sep. 1998. 
[28] D. L. G. Hill, P. G. Batchelor, M. Holden, and D. J. Hawkes, “Medical image registration,” 
Phys. Med. Biol., vol. 46, no. 3, p. R1, Mar. 2001. 
83 
 
[29] S. Klein, M. Staring, and J. P. W. Pluim, “Evaluation of optimization methods for nonrigid 
medical image registration using mutual information and B-splines,” Ieee Trans. Image 
Process. Publ. Ieee Signal Process. Soc., vol. 16, no. 12, pp. 2879–2890, Dec. 2007. 
[30] F. Maes, A. Collignon, D. Vandermeulen, G. Marchal, and P. Suetens, “Multimodality 
image registration by maximization of mutual information,” Ieee Trans. Med. Imaging, vol. 
16, no. 2, pp. 187–198, 1997. 
[31] P. A. Andres and R. A. Isoardi, “Using ITK platform for medical image registration,” J. 
Phys. Conf. Ser., vol. 90, no. 1, p. 012056, Nov. 2007. 
[32] H. Ólafsdóttir, T. A. Darvann, N. V. Hermann, E. Oubel, B. K. Ersbøll, A. F. Frangi, P. 
Larsen, C. A. Perlyn, G. M. Morriss-Kay, and S. Kreiborg, “Computational mouse atlases 
and their application to automatic assessment of craniofacial dysmorphology caused by the 
Crouzon mutation Fgfr2C342Y,” J. Anat., vol. 211, no. 1, pp. 37–52, 2007. 
[33] S. K. Boyd, S. Moser, M. Kuhn, R. J. Klinck, P. L. Krauze, R. Müller, and J. A. Gasser, 
“Evaluation of Three-dimensional Image Registration Methodologies for In Vivo Micro-
computed Tomography,” Ann. Biomed. Eng., vol. 34, no. 10, pp. 1587–1599, Sep. 2006. 
[34] R. Kashani, M. Hub, J. M. Balter, M. L. Kessler, L. Dong, L. Zhang, L. Xing, Y. Xie, D. 
Hawkes, J. A. Schnabel, J. McClelland, S. Joshi, Q. Chen, and W. Lu, “Objective 
assessment of deformable image registration in radiotherapy: a multi-institution study,” 
Med. Phys., vol. 35, no. 12, pp. 5944–5953, Dec. 2008. 
[35] S. Klein, M. Staring, K. Murphy, M. A. Viergever, and J. Pluim, “elastix: A Toolbox for 
Intensity-Based Medical Image Registration,” Ieee Trans. Med. Imaging, vol. 29, no. 1, pp. 
196–205, Jan. 2010. 
[36] A. F. Shields, J. R. Grierson, B. M. Dohmen, H.-J. Machulla, J. C. Stayanoff, J. M. 
Lawhorn-Crews, J. E. Obradovich, O. Muzik, and T. J. Mangner, “Imaging proliferation in 
vivo with [F-18]FLT and positron emission tomography,” Nat. Med., vol. 4, no. 11, pp. 
1334–1336, Nov. 1998. 
[37] A. F. Shields, “PET Imaging with 18F-FLT and Thymidine Analogs: Promise and Pitfalls,” 
J. Nucl. Med., vol. 44, no. 9, pp. 1432–1434, Sep. 2003. 
[38] J. Toyohara, A. Waki, S. Takamatsu, Y. Yonekura, Y. Magata, and Y. Fujibayashi, “Basis 
of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and 
[3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines,” 
Nucl. Med. Biol., vol. 29, no. 3, pp. 281–287, Apr. 2002. 
[39] M. Muzi, H. Vesselle, J. R. Grierson, D. A. Mankoff, R. A. Schmidt, L. Peterson, J. M. 
Wells, and K. A. Krohn, “Kinetic Analysis of 3′-Deoxy-3′-Fluorothymidine PET Studies: 
Validation Studies in Patients with Lung Cancer,” J. Nucl. Med., vol. 46, no. 2, pp. 274–
282, Feb. 2005. 
[40] E. G. C. Troost, J. Bussink, P. J. Slootweg, W. J. M. Peeters, M. A. W. Merkx, A. J. van der 
Kogel, W. J. G. Oyen, and J. H. A. M. Kaanders, “Histopathologic validation of 3’-deoxy-
3’-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity,” J. Nucl. Med. 
Off. Publ. Soc. Nucl. Med., vol. 51, no. 5, pp. 713–719, May 2010. 
[41] C. C. Zhang, Z. Yan, W. Li, K. Kuszpit, C. L. Painter, Q. Zhang, P. B. Lappin, T. Nichols, 
M. E. Lira, T. Affolter, N. R. Fahey, C. Cullinane, M. Spilker, K. Zasadny, P. O’Brien, D. 
Buckman, A. Wong, and J. G. Christensen, “[18F]FLT–PET Imaging Does Not Always 
‘Light Up’ Proliferating Tumor Cells,” Clin. Cancer Res., vol. 18, no. 5, pp. 1303–1312, 
Mar. 2012. 
84 
 
[42] D. C. P. Cobben, P. H. Elsinga, H. J. Hoekstra, A. J. H. Suurmeijer, W. Vaalburg, B. Maas, 
P. L. Jager, and H. M. J. Groen, “Is 18F-3’-fluoro-3’-deoxy-L-thymidine useful for the 
staging and restaging of non-small cell lung cancer?,” J. Nucl. Med. Off. Publ. Soc. Nucl. 
Med., vol. 45, no. 10, pp. 1677–1682, Oct. 2004. 
[43] A. van Waarde, D. C. P. Cobben, A. J. H. Suurmeijer, B. Maas, W. Vaalburg, E. F. J. de 
Vries, P. L. Jager, H. J. Hoekstra, and P. H. Elsinga, “Selectivity of 18F-FLT and 18F-FDG 
for differentiating tumor from inflammation in a rodent model,” J. Nucl. Med. Off. Publ. 
Soc. Nucl. Med., vol. 45, no. 4, pp. 695–700, Apr. 2004. 
[44] H. Dittmann, B. M. Dohmen, F. Paulsen, K. Eichhorn, S. M. Eschmann, M. Horger, M. 
Wehrmann, H. J. Machulla, and R. Bares, “[18F]FLT PET for diagnosis and staging of 
thoracic tumours,” Eur. J. Nucl. Med. Mol. Imaging, vol. 30, no. 10, pp. 1407–1412, Oct. 
2003. 
[45] J. R. Bading and A. F. Shields, “Imaging of cell proliferation: status and prospects,” J. 
Nucl. Med. Off. Publ. Soc. Nucl. Med., vol. 49 Suppl 2, p. 64S–80S, Jun. 2008. 
[46] B. Xu, Z. Guan, C. Liu, R. Wang, D. Yin, J. Zhang, Y. Chen, S. Yao, M. Shao, H. Wang, 
and J. Tian, “Can multimodality imaging using 18F-FDG/18F-FLT PET/CT benefit the 
diagnosis and management of patients with pulmonary lesions?,” Eur. J. Nucl. Med. Mol. 
Imaging, vol. 38, no. 2, pp. 285–292, Feb. 2011. 
[47] A. Salskov, V. S. Tammisetti, J. Grierson, and H. Vesselle, “FLT: measuring tumor cell 
proliferation in vivo with positron emission tomography and 3’-deoxy-3’-
[18F]fluorothymidine,” Semin. Nucl. Med., vol. 37, no. 6, pp. 429–439, Nov. 2007. 
[48] H. L. van Westreenen, D. C. P. Cobben, P. L. Jager, H. M. van Dullemen, J. Wesseling, P. 
H. Elsinga, and J. T. Plukker, “Comparison of 18F-FLT PET and 18F-FDG PET in 
esophageal cancer,” J. Nucl. Med. Off. Publ. Soc. Nucl. Med., vol. 46, no. 3, pp. 400–404, 
Mar. 2005. 
[49] W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, 
J. Czernin, M. E. Phelps, and D. H. S. Silverman, “Imaging proliferation in brain tumors 
with 18F-FLT PET: comparison with 18F-FDG,” J. Nucl. Med. Off. Publ. Soc. Nucl. Med., 
vol. 46, no. 6, pp. 945–952, Jun. 2005. 
[50] H. Hoshikawa, Y. Nishiyama, T. Kishino, Y. Yamamoto, R. Haba, and N. Mori, 
“Comparison of FLT-PET and FDG-PET for visualization of head and neck squamous cell 
cancers,” Mol. Imaging Biol. Mib Off. Publ. Acad. Mol. Imaging, vol. 13, no. 1, pp. 172–
177, Feb. 2011. 
[51] S. R. Bowen, R. J. Chappell, S. M. Bentzen, M. A. Deveau, L. J. Forrest, and R. Jeraj, 
“Spatially resolved regression analysis of pre-treatment FDG, FLT and Cu-ATSM PET 
from post-treatment FDG PET: An exploratory study,” Radiother. Oncol., vol. 105, no. 1, 
pp. 41–48, Oct. 2012. 
[52] B. Vanderstraeten, W. Duthoy, W. De Gersem, W. De Neve, and H. Thierens, 
“[18F]fluoro-deoxy-glucose positron emission tomography ([18F]FDG-PET) voxel 
intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer,” 
Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol., vol. 79, no. 3, pp. 249–258, Jun. 2006. 
[53] I. Madani, W. Duthoy, C. Derie, W. De Gersem, T. Boterberg, M. Saerens, F. Jacobs, V. 
Grégoire, M. Lonneux, L. Vakaet, B. Vanderstraeten, W. Bauters, K. Bonte, H. Thierens, 
and W. De Neve, “Positron emission tomography-guided, focal-dose escalation using 
intensity-modulated radiotherapy for head and neck cancer,” Int. J. Radiat. Oncol. Biol. 
Phys., vol. 68, no. 1, pp. 126–135, May 2007. 
85 
 
[54] J. Wong, E. Armour, P. Kazanzides, I. Iordachita, E. Tryggestad, H. Deng, M. Matinfar, C. 
Kennedy, Z. Liu, T. Chan, O. Gray, F. Verhaegen, T. McNutt, E. Ford, and T. L. DeWeese, 
“A high resolution small animal radiation research platform (SARRP) with x-ray 
tomographic guidance capabilities,” Int. J. Radiat. Oncol. Biol. Phys., vol. 71, no. 5, pp. 
1591–1599, Aug. 2008. 
[55] R. Jacques, R. Taylor, J. Wong, and T. McNutt, “Towards real-time radiation therapy: GPU 
accelerated superposition/convolution,” Comput. Methods Programs Biomed., vol. 98, no. 
3, pp. 285–292, Jun. 2010. 
[56] M. Baumann, W. DuBois, and H. D. Suit, “Response of Human Squamous Cell Carcinoma 
Xenografts of Different Sizes to Irradiation: Relationship of Clonogenic Cells, Cellular 
Radiation Sensitivity in Vivo, and Tumor Rescuing Units,” Radiation Research: Official 
Journal of the Radiation Research Society, 07-May-2010. [Online]. Available: 
http://www.rrjournal.org/doi/abs/10.2307/3577740. [Accessed: 26-Jun-2013]. 
[57] A. L. Zietman, H. D. Suit, K. N. Tomkinson, H. D. Thames, and R. S. Sedlacek, “The 
response of two human tumor xenografts to fractionated irradiation. The derivation of 
alpha/beta ratios from growth delay, tumor control, and in vitro cell survival assays,” Int. J. 
Radiat. Oncol. Biol. Phys., vol. 18, no. 3, pp. 569–575, Mar. 1990. 
[58] M. Stuschke, V. Budach, W. Budach, H. J. Feldmann, and H. Sack, “Radioresponsiveness, 
sublethal damage repair and stem cell rate in spheroids from three human tumor lines: 
comparison with xenograft data,” Int. J. Radiat. Oncol. Biol. Phys., vol. 24, no. 1, pp. 119–
126, 1992. 
[59] E. C. Ford, P. Achanta, D. Purger, M. Armour, J. Reyes, J. Fong, L. Kleinberg, K. 
Redmond, J. Wong, M. H. Jang, H. Jun, H.-J. Song, and A. Quinones-Hinojosa, “Localized 
CT-guided irradiation inhibits neurogenesis in specific regions of the adult mouse brain,” 
Radiat. Res., vol. 175, no. 6, pp. 774–783, Jun. 2011. 
 
 
 
 
 
 
 
 
 
 
86 
 
Appendix I 
In order to appropriately quantify the success of deformable registration algorithms 
within a tumor, external markers had to be introduced to the tumor. The selection of an 
appropriate marker is outlined in this appendix. Table I lists the tested materials, the linear 
attenuation coefficients, the material thicknesses, the exponential photon attenuation for various 
energies. 
 
 
In addition to the listed markers, catheters filled solutions of cesium iodine were also tested. All 
markers were injected into the center of a phantom comprised of approximately 5 mm of steak. 
  
energy (KeV) 
     
 
40 60 80 70 
  
att at 60 KeV att at 70 KeV 
material m/p(40) m/p(60) m/p(80) m/p(70) Density 
width(for 
22g) N/No N/No 
al 0.565 0.277 0.201 0.239 2.69 0.04 0.941017069 0.97461145 
si 0.693 0.319 0.233 0.276 2.32 0.04 0.937713888 0.974712425 
cu 4.88 1.6 0.768 1.184 8.94 0.04 0.174629621 0.654817702 
h2o 0.267 0.205 0.185 0.195 1 0.04 0.989376829 0.992230341 
bone 0.511 0.273 0.209 0.241 1.85 0.04 0.962892022 0.982324085 
poly 0.216 0.186 0.173 0.1795 1.06 0.04 0.99088341 0.992418089 
Polyvinylidene Flouride 0.256 0.189 0.167 0.178 1.78 0.017 0.992283367 0.9946282 
Nylon 0.247 0.19 0.169 0.1795 1.15 0.023 0.993488145 0.995263478 
         AL .9   and Cu .1 0.998 0.409 0.257 0.333 3.315 0.04 0.876047645 0.956804876 
thin copper 4.88 1.6 0.768 1.184 8.94 0.037 0.199048573 0.675945032 
titanium dioxide 1.43 0.536 0.31 0.423 4.23 0.02 0.886053453 0.964846942 
copper&zinc mix 1.84 0.748 0.461 0.6045 3.684 0.01 0.9344608 0.977976361 
         steel 
        
Aluminum Manganese 5.60E-01 
2.76E-
01 
2.01E-
01 
2.38E-
01 2.69 0.04 0.94148295 0.974674373 
 
Table 1: The percent transmission for a photon beam of a specified energy through a marker material 
 
87 
 
Phantoms were imaged at energies of 60 and 70 KeV for the purpose of establishing the extent of 
CT artifact. Figures 54 – 57 depict various markers imaged in the phantom. 
 
 
 
 
 
 
 
 
Figure 54: A CT image of catheters containing various concentrations of iodine 
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Figure 56: The image of a copper composite magnet wire 
 
 
 
Figure 55: Metal artifact caused by a stainless steel acupuncture needle 
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The composite copper wire was originally assumed to be completely copper and is used 
for very small scale electronics like headphones, mp3 players and cellphones. After comparing 
the images of the 22 gauge copper wire and the 22 gauge composite wire it became obvious that 
the wire was not as attenuating as the copper wire. The copper composite wire provided the least 
artifact and was the clearest marker with the exception of iodine. Unfortunately the difficulty of 
producing iodine filled catheters at sizes of approximately a millimeter and the difficulty 
implanting the flexible catheters in the tumors prevented their use. As such the composite copper 
was selected for experiments in chapter 2 of the dissertation. 
 
Figure 57: Metal artifact introduced by a 32 gauge steel wire (left) and a 22 gauge copper 
wire (right) 
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Appendix II 
This appendix shows the results of the voxel by voxel analysis of FDG and FLT images 
using the original reconstructed PET voxel size of .77 mm. These images were not used for 
primary analysis because they exhibit a pixel size smaller than the inherent resolution of the PET 
images. This could potentially cause problems in the correlation analysis. The analysis, however, 
was performed on these images retrospectively for the purposes of comparison. 
Slicer 3 scatterplots using the original .77 mm voxel sizes 
 
 
 
 
Figure 1: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 13L with a 
reconstructed PET resolution of .77 mm 
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Figure 2: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 13R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 3: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 14L with a 
reconstructed PET resolution of .77 mm 
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Figure 4: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 14R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 5: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 16L with a 
reconstructed PET resolution of .77 mm 
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Figure 6: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 16R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 7: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 18L with a 
reconstructed PET resolution of .77 mm 
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Figure 8: A scatterplot showing the changes in FDG and FLT on a voxel by voxel scale for tumor 18R with a 
reconstructed PET resolution of .77 mm 
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Slicer 3 binned graphs using the original .77 mm voxel sizes 
 
 
 
 
 
 
 
 
Figure 9: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 13L with a 
reconstructed PET resolution of .77 mm 
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Figure 10: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 13R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 11: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 14L with a 
reconstructed PET resolution of .77 mm 
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Figure 12: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 14R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 13: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 16L with a 
reconstructed PET resolution of .77 mm 
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Figure 14: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 16R with a 
reconstructed PET resolution of .77 mm 
 
 
Figure 15: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 18L with a 
reconstructed PET resolution of .77 mm 
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Figure 16: A binned graph showing the changes in FDG and FLT on a voxel by voxel scale for tumor 18R with a 
reconstructed PET resolution of .77 mm 
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Appendix III 
 
Since the analysis of these images is dependant upon the image registration method used to 
register the FDG and FLT image sets the analysis was also performed using a Demon’s 
deformation algorithm available in the research version of Pinnacle 9. This algorithm was chosen 
because of its availability in a patient-based treatment planning system as opposed to an open 
source image analysis environment. The analysis used the exact images as the slicer 3 analysis in 
chapter 4 of the dissertation as inputs to image registration. After registration,  images were 
processed using the matlab code from the slicer 3 analysis. Binned graphs and scatterplots were 
generated for images at .77 mm and the 1.5 mm voxel sizes. In addition the Dice coefficient 
overlap analysis was also carried out for these data sets. All data analysis and image post 
processing was preformed in the same manner as in the Slicer 3 B-spline analysis. The following 
sections show the results of analyzing images registered using the pinnacle 9 Demon’s 
deformation algorithm. Image sets of both .77 mm voxel size and the rebinned 1.5 mm voxel size 
were analyzed.  
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Scatterplots of 1.5mm voxel size images registered using Pinnacle 9 Demon’s 
algorithm 
 
 
 
 
 
 
Figure 1: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the FaDu 
tumor 13L 
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Figure 2: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the FaDu 
tumor 13R 
 
 
Figure 3: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the FaDu 
tumor 14L 
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Figure 4: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the FaDu 
tumor 14R 
 
 
Figure 5: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the SQ20B 
tumor 16L 
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Figure 6: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the SQ20B 
tumor 16R 
 
Figure 7: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the SQ20B 
tumor 18L 
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Figure 8: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 18R 
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Binned graphs of 1.5mm voxel size images registered using Pinnacle 9 
Demon’s algorithm 
 
 
 
 
 
 
 
 
Figure 9: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 13L 
 
107 
 
 
 
Figure 10: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 13R 
 
 
Figure 11: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 14L 
108 
 
 
 
Figure 12: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 14R 
 
 
Figure 13: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 16L 
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Figure 14: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 16R 
 
 
Figure 15: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 18L 
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Figure 16: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 18R 
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Scatterplot of .77 voxel size images registered using Pinnacle 9 Demon’s 
algorithm 
 
 
 
 
 
 
 
Figure 16: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 13L with a reconstructed voxel size of .77 mm 
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Figure 17: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 13R with a reconstructed voxel size of .77 mm 
 
 
Figure 18: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 14L with a reconstructed voxel size of .77 mm 
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Figure 19: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
FaDu tumor 14R with a reconstructed voxel size of .77 mm 
 
 
Figure 20: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 16L with a reconstructed voxel size of .77 mm 
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Figure 21: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 16R with a reconstructed voxel size of .77 mm 
 
 
Figure 22: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 18L with a reconstructed voxel size of .77 mm 
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Figure 23: Scatterplot showing the changes in FLT and FDG uptake in each voxel of the PET image for the 
SQ20B tumor 18R with a reconstructed voxel size of .77 mm 
 
116 
 
 
Binned graphs of .77 voxel size images registered using Pinnacle 9 
Demon’s algorithm 
 
 
 
 
 
 
 
 
Figure 24: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image 
for the FaDu tumor 13L with a reconstructed voxel size of .77 mm 
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Figure 25: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 13R with a reconstructed voxel size of .77 mm 
 
 
Figure 26: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 14L with a reconstructed voxel size of .77 mm 
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Figure 27: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the FaDu tumor 14R with a reconstructed voxel size of .77 mm 
 
 
Figure 28: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 16L with a reconstructed voxel size of .77 mm 
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Figure 29: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image for 
the SQ20B tumor 16R with a reconstructed voxel size of .77 mm 
 
 
Figure 30: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image 
for the SQ20B tumor 18L with a reconstructed voxel size of .77 mm 
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The voxel-by-voxel correlation analysis for Pinnacle 9 revealed an average correlation 
coefficient of .562 for FaDu tumors and .625 for SQ20B tumors. Unlike the Slicer 3 analysis, 
however, there was no statistical difference between the strengths of correlation between FaDu 
and SQ20B in the Pinnacle 9 analysis. The Dice similarity volumes overlap analysis revealed 
similar results to those seen in the voxel-by-voxel analyses. The Dice analysis revealed that there 
were significant areas on non-overlap between FDG and FLT depending on how you threshold 
the images. On average using a 50% threshold for both images yielded an overlap of 
approximately 77%. These results imply that the popular idea of auto-segmentation or auto-
thresholding PET images to achieve an ROI to target could potentially cause a geometric miss of 
areas of highly proliferating cells and must be done with extreme caution as you go beyond 
 
Figure 31: Binned graph showing the changes in FLT and FDG uptake in each voxel of the PET image 
for the SQ20B tumor 18R with a reconstructed voxel size of .77 mm 
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threshold values excluding more than approximately 25% of the data. An analysis of the volume 
under the synthetic “Dice surface” yielded average “volume” of 6171.82, an average volume of 
5572.35 for FaDu tumors only and a volume of 6771.3 for SQ20B with no statistical difference 
between the two data sets. 
Dice similarity surfaces images registered using Pinnacle 9 Demon’s 
algorithm 
 
 
 
 
Figure 32: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for FaDu tumor 13L 
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Figure 33: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for FaDu tumor 13R 
 
 
Figure 34: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for FaDu tumor 14L 
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Figure 35: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for FaDu tumor 14R 
 
 
Figure 36: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for SQ20B tumor 16L 
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Figure 37: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for SQ20B tumor 16R 
 
 
Figure 38: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for SQ20B tumor 18L 
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The results of the Slicer analysis support the histological data while the results of the 
Pinnacle 9 analysis support the data but are not statistically significant. There are a number of 
reasons that the Pinnacle 9 analysis could differ. The generation and analysis of the various 
regions of interest, contours and image intensities were as objective as possible for the Slicer and 
Pinnacle analyses. All ROIs used for deformation were created using auto-thresholding for both 
methodologies. The tumor contours were generated manually using the CT data sets by the same 
researcher for both Pinnacle 9 and Slicer situations. The major differences between the two 
procedures involve the scaling of the images by Pinnacle 9 and the process of exporting and 
analyzing the images from both systems. In the case of the Slicer system, the images and 
 
Figure 39: A plot showing the change the spatial overlap between FDG and FLT sub-volumes defined by 
thresholding PET images at different percentages of maximum intensity for SQ20B tumor 18R 
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contours were saved in the same format and same resolutions each step of the way, this preserves 
the integrity of the user-generated contours across all steps. The deformed PET images produced 
using Pinnacle 9 are automatically scaled to the sizes of the CT image sets which are 
significantly larger and higher resolution than the original PET images. After export, these PET 
images and contours must be rescaled to match the original resolutions. The deformed image sets 
also do not include any rigid shifts applied by Pinnacle 9 once they are exported. This requires 
another registration after exportation of the image sets. In contrast, the Slicer results are all 
consistently kept at a single resolution and require no special exporting procedures. Pinnacle 9 
also takes into account scaling factors in the PET images once they are loaded into the Pinnacle 
system. This scaling factor is produced by the small animal imaging device however, the two 
devices are designed by competing manufacturers and for different purposes and do not seem to 
handle scaling factors in the same manner. 
The analysis of these image sets with a different algorithm verifies that the hypothesis that 
the results of comparing biological images are very sensitive to algorithm selection and image 
post processing. It is best to limit the amount of post processing of registered images as much as 
possible to prevent skewing of results. The B-spline registration available in Slicer registered all 
image sets successfully and produced the most accurate registrations. 
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